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Abstract  
There is inadequate information on the fetal safety of drugs during 
pregnancy for the majority of marketed drugs. It is challenging to examine 
the safety and efficacy of drugs during pregnancy due to the ethical issues of 
exposing unborn babies to these chemicals. It often takes many years before 
associations between a drug and its safety, efficacy, and toxicity in 
pregnancy can be established. This thesis will examine strategies in signal 
detection of the effects of drug exposures during pregnancy. 
Meta-analyses have become useful in the area of clinical teratology. 
Observational studies provide the main source of information in these meta-
analyses. Although the quality of meta-analysis of small observational 
studies is challenging, it is an effective strategy, as shown in the present 
study, in predicting correct signals to estimate teratogenicity years before 
large cohort studies become available.  
Results of retrospective pregnancy registries are commonly reported 
in regulatory documentations. However, little data are available on the 
precision of the estimates from such registries. The present study confirms a 
consistent bias against the null hypothesis in a retrospective registry which 
needs to be considered when interpreting such data as a strategy in 
generating safety/risk signals of new drugs. 
H1 antihistamines are used for the treatment of nausea and vomiting 
during pregnancy as well as the symptomatic relief of allergy. Although they 
are felt to be safe, several studies have challenged this assumption. By using 
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meta-analysis, the safety of antihistamines has been confirmed in this thesis 
with over 1.3 million exposed and control subjects.  
Typically, after experimental animal studies, novel therapeutic 
modalities are tested by randomized controlled trials. Cumulative meta-
analysis is an effective strategy to detect a possible time- dependent effect 
and potential bias against the null hypothesis, whether antioxidant treatment 
decreases the rates of preeclampsia. I have shown that the initial favorable 
effect seen in the first studies is nullified as the sample sizes and number of 
studies is increased. 
There is a need to continue using and developing the above strategies 
to study the safety and efficacy of drugs to improve maternal fetal health. 
Keywords 
Meta-analysis, Pregnancy outcomes, Retrospective pregnancy registries, H1 
antihistamine, Cumulative meta-analysis. 
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Chapter 1: General introduction. 
 Presently, it often takes many years before any association is established 
between a drug and its toxicity, safety, and/or efficacy in pregnancy are 
established. With 50% of all pregnancies being unplanned [1], large numbers of 
women are exposed inadvertently to medications in early pregnancy. In addition, 
many pregnant women suffer from conditions that require continued treatment 
during pregnancy [2]; therefore, there is a need to be able to identify fetal risks as 
soon as possible. This ‘integrated articles’ thesis is based on five articles I have 
published over the last four years, all focusing on signal detection of the effects of 
exposures during pregnancy. 
1.1. Understanding the role of meta-analysis in maternal-fetal health research. 
Usually, randomized controlled drug studies cannot include pregnant women 
due to ethical issues surrounding the fear of potential teratogenic risk given the 
unknown safety profile of the new drugs. Therefore, prenatal adverse drug effect 
data are rarely known from such sources. Some pregnant women may be exposed 
to a new drug in the premarketing phase unintentionally; hence data are often 
collected in retrospective or prospective observations. Thus, post marketing 
epidemiological studies based on observational data are the main methods by 
which to study potential teratogenic effects when randomization is impossible [3]. 
 However, over the past two decades, systematic reviews and meta-analyses 
of observational studies have been increasingly utilized in the field of clinical 
teratology as part of the general trend of a 500-fold increase in publications [4]. A 
systematic review is defined as “the application of scientific strategies that limit 
bias by a systematic assembly, critical appraisal, and synthesis of all relevant 
studies on a specific topic” [5]. In clinical teratology, the specific topic is typically 
the risks of major congenital malformations, miscarriage, or prematurity in the 
1 
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exposed versus non-exposed groups, or the long term neurodevelopmental effects 
of in-utero exposure [6]. Meta-analysis is defined as the statistical synthesis of 
results from several independent, but ‘combinable’ studies, leading to a 
quantitative summary of the pooled results [5].  
In the hierarchy of studies, meta-analyses and systematic reviews of 
randomized studies are ranked at the highest level of evidence. In contrast, 
systematic reviews and meta-analyses of observational studies possess more 
weaknesses and potential biases. Reporting of observational research is often not 
detailed and clear enough to assess the strengths and weaknesses of the 
investigations [7]. Furthermore, multiple deficiencies, such as heterogeneity [8], 
methodological quality [9], deficiencies in statistical methods [10], and controlling 
for all potential sources of bias [11], have been widely reported. As a result, the 
quality of published meta-analyses of observational studies ranges widely and the 
conclusions reached from the same set of studies may be conflicting. 
 Typically, after a new drug is introduced into the market, case reports, case 
series, and small, underpowered controlled cohort studies begin to emerge. 
Synthesizing these small studies in meta-analyses allows for an increase in sample 
size and, hence in the power to distinguish relatively small teratological signals. 
Only much later, when the drug has been used on a large scale, are large cohort 
studies published, and they are sufficiently powered to draw more solid 
conclusions on fetal safety/ risks. 
There is a need to study and examine the validity of the conclusions reached 
by meta-analyses of small observational teratology studies as compared with the 
newer, very large studies. As meta-analyses of small observational studies are 
available years before large, appropriately powered cohort studies become 
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available, they may be important to consider in clinical counseling. It is therefore 
logical to try to estimate how early a valid signal (positive or negative) can be 
generated from meta-analyses before the large cohort studies are published 
(Chapter 3). 
1.2. Understanding the role of retrospective pregnancy exposure registries in 
maternal-fetal health research. 
Another important strategy to assess drug safety during pregnancy, 
employed mostly by drug companies, is using pregnancy exposure registries. 
Prospective pregnancy exposure registries, where pregnant women are enrolled 
before the outcomes of their pregnancies are known, are recognized as an 
important method for ascertaining risks associated with a drug exposure during 
pregnancy. In contrast, retrospective pregnancy exposure registries are based on 
women/physicians contacting the registry after pregnancy outcomes are known. 
Retrospective registries have been regarded as the weakest type of teratogenic 
evidence and were never viewed by clinicians and scientists as data that can lead to 
quantitative estimates of risk/safety. However, is this viewpoint justified?  
There is a reporting bias that makes interpretation of retrospective pregnancy 
exposure registries challenging [12]. Until now, this type of bias has led clinicians, 
scientists and regulatory bodies to discard such data. But if the bias leads to a 
stable increase in signal, it may also mean that, if the retrospective study does not 
show malformation rates above the expected baseline of 3-5%, the drug is probably 
not associated with an increased teratogenic risk. Since most medicinal drugs are 
not teratogenic [13], the ability to use such data may empower women and their 
health professionals to use much needed drugs years before large prospective 
studies are conducted.  
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There is a need to compare the rates of reported malformations in 
retrospective pregnancy exposure registries vs. prospective pregnancy exposure of 
the same kind of drug at the same period of time via the same drug company in an 
effort to make the retrospective registries more useable and more a part of the 
overall analysis of teratogenicity (Chapter 4).  
1.3. Applying meta-analysis to address unresolved research question in 
teratology with H1 antihistamine as an example. 
H1 antihistamine is classified as either the first or old generation H1 
antihistamine such as hydroxyzine or as the second or new generation H1 
antihistamine such as cetirizine. The first generation class of H1 antihistamine has 
the ability to cross the blood brain barrier which can be considered a disadvantage 
when we want to treat allergy because it will cause a sedative side effect. However 
crossing the blood brain barrier can be an advantage when we want to treat nausea 
and vomiting during pregnancy (NVP). The second generation class of H1 
antihistamine has less ability to cross the blood brain barrier which gives this class 
a big advantage when we want to treat allergy or asthma without the sedative side 
effect [14]. 
The best approach to quantify the safety/risk of H1 antihistamine during 
pregnancy is to conduct a meta-analysis of all available observational control 
studies and this is what Seto and his colleagues did twenty years ago and they 
concluded that H1 antihistamine can be safely used during pregnancy [15]. 
Another research group re-analyzed the Seto meta-analysis without adding new 
research and they found contradictory results [16]. Therefore, there is a need to 
conduct more observational studies on H1 antihistamines and also conduct a new 
meta-analysis on all available studies on H1 antihistamines to assess the risk of 
malformation and other pregnancy outcomes. We focused on assessing the safety 
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of using cetirizine and its prodrug hydroxyzine during the first trimester by 
conducting meta-analyses of the current and all available cohort studies that 
studied adverse pregnancy outcomes.   
The current meta-analyses focus primarily on first trimester exposure. This 
was accomplished by including studies where the first trimester exposure to H1 
antihistamines was necessary. Studies where mothers were also exposed in 
subsequent trimesters were included but this was not a requirement. The reasons 
for focusing on the first trimester exposure are twofold. First of all, the first 
trimester is a critical time for fetal development and thus an extremely important 
period for assessing the potential adverse effects of drugs. Gross structural 
abnormalities, which can be readily apparent in newborns, occur following 
exposure to teratogenic agents during this stage of organogenesis, when tissues and 
organs are developing [17]. As a result, most studies assessing the effects of drug 
exposure during pregnancy typically look at the first trimester exposure or view 
this timing of exposure as important.  
Presently there is sufficient research to power a safety analysis given the 
large number of studies focusing on first trimester exposure. This can be partly 
caused by the commonplace use of H1 antihistamines during the first trimester. A 
woman may be given H1 antihistamines intentionally to treat NVP or another 
condition that presents during the first trimester. Alternatively, with 50% of 
pregnancies being unplanned [1], a woman may take prescribed or over the counter 
H1 antihistamines for treatment of a medical condition while being unaware of her 
pregnancy. Therefore, it is necessary to adequately and accurately assess the risks 
associated with H1 antihistamine use through meta-analysis (Chapter 5 and 
Chapter 6).  
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1.4. Cumulative meta-analysis as a tool in detecting the emergence of evidence 
in teratology, treatment of preeclampsia as an example.  
Meta-analysis in general is not a statistical method that simply combines 
results from different studies and aggregates them as a large study. In meta-
analysis, studies that include larger sample sizes and a lesser degree of variabilities 
are weighted more than other smaller studies. In meta-analysis there are two 
models, fixed effect and random effect. Fixed effect model is usually used when 
the studies come from the same research group and are highly homogenous. On the 
other hand, the random effect model is used when the studies come from different 
research groups. The big difference between the two models is the weighting of the 
studies. Studies with a smaller sample size have more weight (credit) in the 
random effect model estimate than on the fixed effect model estimate [18].   
The forest plot is the results figure of a typical meta-analysis. This figure 
shows the effect measure of each study (like risk ratio or odds ratio) as well as its 
confidence interval and the weighted level. Also, the forest plot shows the 
summary of the overall effect measure and its confidence interval.  
In case of cumulative meta-analysis, the result of the studies are 
accumulated from the earliest to the latest, in a way that each new study includes a 
synthesis of all prior studies. This sequential combining of the studies’ results has 
an advantage of viewing whether there is consistency in the results of consecutive 
studies or if there is change in the direction of the overall estimate when more 
recent studies are added [18].  
Taking the advantage of cumulative meta-analysis, the researcher can use it 
as a tool in detecting the emergence of evidence especially after a new remedy for 
pregnancy complications enters the market. Conducting cumulative meta-analysis 
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to examine changes over time in the pooled effect size of randomized control trials 
published on the protective effects of antioxidants and low dose aspirin against 
preeclampsia is used in this thesis to predict the potential bias against the null 
hypothesis (Chapter 7). 
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Chapter 2: Objectives and hypotheses. 
2.1. Objectives. 
1) To systematically review the literature to examine the validity of the 
conclusions reached by meta-analyses of small observational studies by comparing 
the results reached in these meta-analyses with more recent, large, 
methodologically superior studies published on the same topic at a later date. 
2) To compare the rates of major congenital malformations reported in 
retrospective versus prospective registries of the same drug to quantify the 
potential bias of retrospective reports. 
3) To systematically review the literature to conduct meta-analyses to 
measure the rate of adverse pregnancy outcomes of cetirizine and all H1-
antihistamines after the first trimester exposure.  
4) To conduct cumulative meta-analyses to examine changes over time in 
the pooled effect size of randomized control trials published on the protective 
effects of antioxidants and low dose aspirin against preeclampsia, and to identify 
determinants that may affect such changes. 
2.2. Hypotheses. 
1) The direction of the conclusions reached by meta-analyses of small 
studies on several teratology topics are similar to the results reached by more 
recent, large, methodologically superior studies published on the same topic at a 
later date. 
2) There is a systematic bias of retrospective registries when the rates of 
major congenital malformations reported in retrospective registries are much 
higher than prospective registries of the same drug, which also suggests that if the 
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retrospective registries did not show increase in major congenital malformations 
above the baseline risk, the drug is probably not a major teratogen. 
3) The use of cetirizine and all H1-antihistamines during the first trimester is 
not associated with an increased risk of adverse pregnancy outcomes. 
4) Cumulative meta-analysis is an effective tool in predicting potential bias 
against the null hypothesis of randomized control trials published on the protective 
effects of antioxidants and low dose aspirin against preeclampsia. 
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Chapter 3: The role of meta-analyses in identifying human teratogenicity. 
This chapter has been published previously as part of a book chapter.  
Etwel F, Hutson JR, Madadi P, Gareri J, Koren G. Fetal and perinatal exposure to 
drugs and chemicals: novel biomarkers of risk. Annu Rev Pharmacol Toxicol. 
2014; 54:295-315.  
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3.1. Introduction. 
Typically, randomized controlled drug studies exclude pregnant women 
owing to fear of teratogenic risk. As a result, prenatal adverse drug effects data are 
rarely available from randomized trials, and epidemiological studies based on 
observational data constitute the main data source [1]. 
Reporting of observational research is often not sufficiently detailed and 
clear to assess the potential strengths and weaknesses of these investigations. 
Multiple deficiencies such as heterogeneity, methodological quality, insufficient 
statistical methods, and control of potential sources of bias have been widely 
recognized [2, 3]. 
Typically, after many years during which small cohort studies report on fetal 
safety/risk of a particular drug, administrative databases may report on large 
numbers of patients exposed to that agent. Although the strength of these studies 
lies in their large size, these large cohort studies take many years to conduct and 
are published long after the small cohort studies are published. The synthesis of 
these small cohort studies into a systematic review and meta-analysis may yield an 
important early signal for the safety/risk of drug use in pregnancy. 
Over the past two decades, such systematic reviews and meta-analyses of 
observational studies have been increasingly published in the field of clinical 
teratology [4]. To date, the conclusions reached by meta-analyses of small 
observational teratological studies have not been validated through comparison 
with those reached by more recent, very large cohort studies. 
3.2. Methods.  
As the first step in validating such conclusions, we identified all meta-
analyses of small observational teratological studies published in peer review 
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journals. Meta-analyses were eligible for consideration if the outcome measures 
were the risk of congenital malformation and/or the risk of long-term 
neurodevelopment of children after in utero exposure to therapeutic drugs in the 
first trimester of pregnancy. 
As the second step, we identified subsequently published large teratological 
cohort studies on the same drug addressing the same endpoint. Large cohort studies 
were judged suitable for inclusion in this review if the number of women exposed 
to the drug in question exceeded either 1,000 or the combined number of total 
cases in the corresponding meta-analysis.  
3.3. Results. 
Of more than 60 meta-analyses on medicinal drugs published by December 
31, 2012, 9 meta-analyses could be matched to large, later cohort studies on the 
same drug (Table 3). There were 7 “negative” meta-analyses (i.e., showing no 
teratological effects) and 2 “positive” ones (showing either morphological or 
developmental adverse effects). In all 9 instances, the meta-analyses accurately 
predicted the results of the later, large cohort studies. The AMSTAR scores were in 
the medium range in all 9 meta-analyses, and the MINORS quality score of the 
large cohort studies was 17.9 ± 1.4 (mean ± standard deviation), which is 
considered to be on the border of “good” quality (Appendix 2: Detailed 
characteristics of the included studies). 
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Table 3. Characteristics of the nine meta-analyses included in the comparison 
with large cohort studies 
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  CI: Confidence Interval, MA: Meta-Analysis, MM: Major Malformations, OR: Odds Ratio, 
RR: Relative Risk. 
  
Type of exposure 
and outcome 
MA 
reference 
Association 
measure  
(95% CI) 
Large 
study 
reference 
Association measure 
(95% CI) 
Benzodiazepines and 
MM 
[7] OR = 0.90 (0.61-
1.35) 
[8] OR = 1.12 (0.91-1.36) 
Untreated epilepsy 
and MM 
[9] OR = 1.92 (0.92-
4.00) 
[10] OR = 1.00 (0.8-1.4) 
Proton-pump 
inhibitors and MM 
[11] RR = 1.18 (0.72-
1.94) 
[12] OR = 1.10 (0.91-1.34) 
H2 blockers and 
MM 
[13] OR = 0.99  (0.60-
1.65) 
[14] OR = 1.14 (0.89-1.45) 
ACE inhibitors and 
MM 
[15] OR = 1.41 (0.66-
3.04) 
[16] OR = 1.12 (0.83-1.49) 
Valproic acid and 
MM 
[17] RR = 3.77 (2.18 -
6.52) 
[18] (Spina bifida)          
RR = 12.7 (7.7-20.7) 
Valproic acid and 
reduction in IQ 
[19] P = 0.001 [20] P = 0.009 
Carbamazepine and 
reduction in IQ 
[19] P = 0.39 [20] P = 0.20 
Varicella infection 
and MM 
[21] Risk = 2.2 %            
(0-4.6%) 
[22] Risk = 0.4%           
(0.05-1.5%) 
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3.4. Discussion. 
It is encouraging that meta-analyses of earlier, albeit smaller, cohort studies 
tend to generate an accurate overall teratogenic signal in estimating human 
teratogenicity years before large and methodologically superior cohort studies are 
published. The meta-analyses offer clinicians, scientists, and regulators an earlier 
signal for the presence or lack of teratogenic risk and hence can have an important 
impact on clinical practice. 
3.5. Conclusion. 
Meta-analyses of small cohort studies of pregnancy outcome appropriately 
predict results of large cohort studies. 
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Chapter 4: Bias against the null hypothesis in retrospective registries of 
gestational drug exposure.  
This chapter has been accepted for publication (in press): 
Etwel F, Koren G. Bias against the Null Hypothesis in Retrospective Registries of 
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4.1. Introduction. 
Typically, medications for use in humans are introduced to the market 
supported by reproductive animal data, which are often not predictive of the risk of 
human malformation. Furthermore, in pre-marketing clinical trials, accidental 
exposures to a medication during pregnancy are typically very rare [1]. However, 
because 50% of all pregnancies are unplanned [2], large numbers of women are 
exposed inadvertently to medications in early pregnancy. Moreover, many 
pregnant women suffer from conditions that require continued treatment during 
pregnancy. When a new drug enters the market, case reports of fetal exposure 
begin to emerge, but unless a very highly teratogenic signal and a unique 
phenotype are evident (such as was noted with thalidomide or isotretinoin) [3], it 
takes years before a prospective cohort study of first trimester fetal exposure 
becomes available. 
Historically, most information about the risks of drugs in pregnancy has 
arisen from findings of spontaneous adverse event reports (case reports). This 
mechanism of passive surveillance has been well-described [4] and is 
advantageous in the identification of a rare or unusual fetal outcome. A major 
limitation of retrospective case series is the lack of denominator data, which 
precludes estimation of the size of risk with use of the drug compared to the risk in 
the general population. 
Retrospective registries of exposure during pregnancy (enrolment in which 
follows notification by families or physicians after the pregnancy outcome is 
known) are typically established by drug companies as part of the regulatory 
process and their contents are often reported in the peer-reviewed literature. 
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The main concern regarding the interpretation of findings in these registries 
is that families with malformed children exposed to a given drug in pregnancy, or 
their physicians, will be more likely to report the malformation to registries than 
families with healthy children prenatally exposed to the same drug [5]. However, 
there is little information available on the precision of the estimates from such 
registries. In 1999, our group documented that the rate of major malformation 
associated with the antifungal itraconazole was 13% in the retrospective report 
collected by the manufacturer, but was only 3.2% in the prospective report 
collected by the same company [5]. Since then, however, the hypothesis that 
retrospective registries are biased towards higher rates of malformations has not 
been further confirmed. 
Because most medications are not teratogenic [6], a potentially false 
teratogenic signal may elicit anxiety and may lead women not to treat serious 
medical conditions. In at least one class of drugs (the statins), a report of adverse 
fetal outcomes based on retrospective surveillance [7] led to high levels of anxiety. 
However, the adverse fetal outcomes were later shown in a meta-analysis of 
prospective studies not to be associated with exposure to statins [8]. 
The objective of the present study was to compare the rates of major 
congenital malformations reported in retrospective and prospective registries for 
the same drug to quantify the potential bias of retrospective reports. 
4.2. Methods. 
We performed a search of the electronic database PubMed from inception to 
December 31 2013 for all available full English texts, using the following search 
terms: “retrospective pregnancy registry”, “prospective pregnancy registry”, 
“reporting bias”, “drug company”, “drug registry”, and combining them with 
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“congenital malformations” or “embryopathy”. In addition, several pregnancy 
registry annual reports that were documented by drug companies and received by 
the Motherisk program at the Hospital for Sick Children in Toronto were reviewed 
for the period 1984 to 2011. Motherisk regularly receives these reports upon their 
release. 
For this analysis, we included published articles and registry reports that 
provided data on rates of major malformations in the offspring of women who 
were exposed to the specific drug during the first trimester of pregnancy, derived 
from both retrospective and prospective registries for the same drug.  
The following information was recorded from the registries for each drug: 
the total number of major malformations among live born infants; the number of 
stillbirths or terminated pregnancies (the numerator); and the total number of 
reported live births, stillbirths, elective pregnancy terminations, and miscarriages 
(the denominator). 
The reported rates of major malformations in the retrospective and 
prospective reports from the same registry for the same drug were compared using 
Fisher’s exact test. Odds ratios and 95% confidence intervals were also calculated. 
The distribution of malformations in each report was compared to the normal 
distribution of birth defects reported in the United States, in order to identify 
whether there was a specific pattern of malformations [9]. 
4.3. Results. 
The electronic search identified a total of 1316 published articles. After 
removing all animal studies, case reports, controlled observational studies, and 
review articles without original data, 122 articles were reviewed in detail. Five 
drugs or classes of drug identified in peer-reviewed published articles fulfilled the 
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inclusion criteria (itraconazole, fluoxetine, acyclovir, statins, and mefloquine) [5, 
10-13]. Three drugs from drug company annual reports also met the inclusion 
criteria (quetiapine, quadrivalent human papillomavirus vaccine, and montelukast 
sodium). In all cases, the rates of major malformations after exposure to these 
drugs were significantly higher in data reported retrospectively than in data 
reported prospectively (Table 4). For all drugs studied, estimates of major 
congenital malformation rates from retrospective registries were higher than from 
prospective registries; the median bias was higher by a factor of 4.18 ± 1.23 (range 
2.13 to 5.97). For six of these drugs the breakdown of malformations was available 
in the reports, and there was no specific pattern of malformations in any of them 
(data not shown). Details of each of the eight drug registries can be found in the 
Appendix 3. 
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Table 4. Rates of major malformation in the eligible registries. 
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Drug name 
Retrospective data Prospective data Increased 
rate* 
P 
for 
difference 
OR 
(95% CI) 
No. of 
cases with 
malforma
tion / 
total No. 
of cases 
Rate (%) 
 (95% CI) 
 
No. of 
cases with 
malformat
ion/ total 
No. of 
cases  
Rate (%) 
(95% CI) 
 
   
Quetiapine 20/253 7.91 
(5.2 to 
11.9) 
 
6/224 2.68 
(1.2 to 5.8) 
 
2.95 0.014 3.12 
(1.23 to 7.91) 
Quadrivalent 
human 
papillomavirus 
vaccine 
12/261 4.60 
(2.6 to 7.9 ) 
 
24/1113 2.16 
(1.4 to 3.2) 
 
2.13 0.049 2.19 
(1.08 to 4.43) 
Montelukast Na 11/66 16.67 
(9.5 to 
27.6) 
 
8/250 3.20 
(1.6 to 6.3) 
 
5.21 <0.001 6.05 
(2.32 to 
15.75) 
Itraconazole 17/166 10.24 
(6.5 to 
15.9) 
 
5/199 2.51 
(1.0 to 5.9) 
 
4.08 0.003 4.43 
(1.60 to 
12.27) 
Fluoxetine 89/426 20.89 
(17.3 to 
25.0) 
 
23/658 3.50 
(2.3 to 5.2) 
 
5.97 <0.001 7.29 
(4.52 to 
11.75) 
Acyclovir 7/31 22.58 
(11.2 to 
40.4) 
 
5/101 4.95 
(2.1 to 
11.3) 
 
4.56 0.007 5.60 
(1.63 to 
19.19) 
Statins 13/91 14.29 
(8.5 to 
23.1) 
 
6/158 3.80 
(1.7 to 8.2) 
 
3.76 0.005 4.22 
(1.55 to 
11.54) 
Mefloquine 29/115 25.22 
(18.1 to 
33.9) 
 
38/717 5.30 
(3.9 to 7.2) 
 
4.76 <0.001 6.03 
(3.54 to 
10.27) 
*Increased rate is equal to the retrospective risk percentage divided by prospective risk 
percentage 
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4.4. Discussion. 
In all available registries with both prospective and retrospective collection 
of data for the same drug, we found consistently higher rates of congenital 
malformations in the reports based on retrospective data collection. The powerful 
impact of reporting the results of a retrospective data collection became evident 
when Edison and Muenke claimed (based on case reports) that statins increased 
teratogenic risk [7]; this claim supported a category X labelling (“the risks 
involved in use of the drug in pregnant women clearly outweigh potential 
benefits”) for this class of drugs by the Food and Drug Administration in the 
United States. However, an increasing number of prospective controlled cohort 
studies and a meta-analysis have failed to show such an association [8]. 
Retrospective data collection appears therefore to result in reporting bias; this 
reporting bias can lead to high levels of anxiety and misperception among women 
and their health professionals, leading even to the termination of otherwise wanted 
pregnancies [6]. 
This significant reporting bias of registries with spontaneous retrospective 
data collection does not apply to controlled retrospective observational studies, 
such as case-control or retrospective cohort studies. Typically, in controlled 
retrospective studies the measurement of exposure to drugs is not correlated with 
the measurement of outcomes, contrary to drug companies' reports [14]. 
Because, in all cases, the bias against the null hypothesis in retrospective 
registries was evident and consistent, an additional hypothesis may be considered. 
In conditions in which the retrospective registry for a particular drug does not show 
malformation rates above the expected baseline of 3% to 5%, the drug is unlikely 
to be associated with a clinically significant increase in teratogenic risk. 
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To begin examining this hypothesis, we considered the effects of 
thiopurines, which are widely used in the management of inflammatory bowel 
disease and other autoimmune conditions. The first retrospective study of 
teratogenic effects associated with this drug class reported 31 exposed cases, with 
only one case with malformation, which was attributed to another drug [15]. Hence 
the malformation rate associated with thiopurines identified in this retrospective 
registry was in the range of the 3-5% baseline risk. Agreeing with this study, two 
separate meta-analyses of all prospective thiopurine studies suggested that 
maternal exposure to this class of medications was not associated with increased 
teratogenic risk [16, 17]. This hypothesis will have to be confirmed by additional 
research.  
4.5. Conclusion. 
Our findings confirm that when data related to malformations associated 
with drug use in pregnancy are collected in registries retrospectively, studies based 
on these data have a major and consistent bias against the null hypothesis. This 
bias must be considered when interpreting the findings of such studies. 
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Chapter 5: The fetal safety of cetirizine: An observational cohort study and 
meta-analysis. 
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5.1. Introduction. 
Second-generation antihistamines (astemizole, loratadine, cetirizine, and 
fexofenadine) provide symptomatic relief of allergic disorders without the adverse 
effects of first-generation antihistamines, mostly CNS and anticholinergic effects. 
Second-generation antihistamines are preferred particularly by patients with a 
higher risk for development of adverse effects, including sedation and impairment 
sleep architecture [1, 2].  
Cetirizine hydrochloride (Reactine)®, a nonprescription selective, second-
generation histamine (H1) receptor antagonist, is a major active metabolite of 
hydroxyzine (first-generation antihistamines) with anti-allergic, antihistaminic and 
anti-inflammatory effects. Cetirizine is the most potent antihistamine available and 
more effective than loratadine and other H1 receptor antagonists in inhibiting 
histamine induced wheal response (swelling) and flare response (vasodilation) [3]. 
Due to its high potency, cetirizine may be appropriate for most severe allergy 
symptoms that are unresponsive to other antihistamines. It has a rapid onset, a long 
duration of activity and low potential for interaction with drugs that are 
metabolized by the hepatic cytochrome P450 system [3, 4]. 
It is estimated that up to 20%-30% of women of childbearing age experience 
allergic rhinitis and 4%-7% suffer from asthma during pregnancy, making them 
two of the most common groups of medical conditions that complicate pregnancy. 
The symptoms may vary from mild (sneezing, itching), which commonly can be 
relieved by avoiding the source of allergy, to severe nasal obstruction that may 
require pharmacotherapy [5]. Product labels state that medications for allergic 
rhinitis should be avoided during pregnancy due to lack of fetal safety data [6] and 
because half of all pregnancies are unplanned [7], this may lead to fetal exposure to 
antihistamine before a woman knows she is pregnant. 
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No teratogenic effects were detected with oral cetirizine doses of 60, 188 
and 133 times the maximum clinically studied human dose in mice, rats and 
rabbits, respectively [8]. However, the animal studies are not necessarily indicative 
of adverse effects during pregnancy at clinically relevant doses and are not always 
predictive of human response. There are limited human studies reporting cetirizine 
exposure in pregnancy and pregnancy outcomes. A small prospective, comparative 
study conducted by Motherisk following 39 mothers exposed to cetirizine (37 in 
the first trimester) did not find differences in pregnancy outcomes between the 
exposed and comparison groups [9]. The most recent data were from the Berlin 
teratogen information service, with 196 women exposed in any trimester (11% in 
the first trimester), also not showing increased risk of birth defects or other adverse 
outcomes [10]. A recent review from the Food and Drug Administration with the 
American College of Allergy, Asthma, Immunology and American College of 
Obstetrics and Gynecology stated that cetirizine should be considered mainly for 
the second and third semester of pregnancy as a second generation agent for 
allergic condition in pregnancy if first generation antihistamine agents are not 
tolerable [11]. These statements suggest to patients and health care providers that 
the fetal safety of cetirizine is still questioned. Because half of all pregnancies are 
unplanned, this type of message may increase anxiety among many exposed 
women. 
Hence, our study objectives were as follows: the primary objective was to 
determine whether cetirizine hydrochloride exposure during the first trimester of 
human pregnancy is associated with an increased rate of major birth defects above 
the baseline rate of 2-5% in the general population. The secondary objective was to 
determine the rates of spontaneous abortions, stillbirths, birth weight and neonatal 
complications following cetirizine hydrochloride exposure. 
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5.2. Methods. 
This study includes an observational cohort study and a meta-analysis of all 
available studies to date.  
5.2.1. Observational cohort study. 
5.2.1.1. Study design.  
This was a prospectively collected observational cohort study. 
5.2.1.2. Settings.  
This study was conducted at the Motherisk Program located at the Hospital 
for Sick Children in Toronto. The Motherisk Program is a counseling service that 
provides pregnant, breastfeeding women, and health professionals information on 
the safety and risks of exposures to prescription and over-the-counter medications, 
natural health products, chemicals, radiation, and infectious diseases [12]. Women 
who called the Motherisk Program between January 1, 2004 and December 31, 
2007 were enrolled. 
5.2.1.3. Study participants.  
Three groups of women were recruited. The first group included pregnant 
women exposed to cetirizine hydrochloride during the first trimester of pregnancy. 
The second group included women who called the general Motherisk line about 
exposure to non-teratogenic agents (control group). The control group was 
matched to the study group (first group) according to maternal age at the time of 
conception (± 2 years) and gestational age at the time of first call to Motherisk (± 2 
weeks). The third group included pregnant women exposed to cetirizine 
hydrochloride during the second and/or third trimester of pregnancy (disease 
matched non first trimester exposure).  
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5.2.1.4. Inclusion criteria. 
1. Women who contacted Motherisk regarding information on the safety or risk of 
using cetirizine hydrochloride for the treatment of seasonal allergic rhinitis, 
chronic idiopathic urticaria and any other allergy at any stage of pregnancy.  
2. Women who contacted Motherisk regarding information on the safety of 
vitamins or other non-teratogenic exposures (i.e. Tylenol, etc.) at any stage of their 
pregnancy. 
5.2.1.5. Exclusion criteria.  
1. Women who were exposed to teratogenic agents (e.g. anticonvulsants, 
isotretinoin, warfarin). 
2. Women with medical conditions that may be associated with birth defects or any 
pregnancy complications (e.g. diabetes, alcohol abuse). 
5.2.1.6. Data collection.  
All women in the study group were recruited when they first contacted the 
Motherisk program regarding the safety of cetirizine hydrochloride during 
pregnancy. At the time of their first call, the study protocol was explained and oral 
informed consent was obtained. At this initial call, we collected demographic data, 
general health information, and information on exposure to any drugs used 
concomitantly with a special focus on the details about cetirizine exposure (dose, 
duration and adverse effects) on a previously developed structural questionnaire. 
The women were re-interviewed 6 months or more after delivery to obtain 
outcome data using standardized follow-up forms. In addition, the mothers’ pre-
pregnancy weight and weight at the time of delivery were recorded. Subsequent to 
the completion of the pregnancy follow-up and in order to confirm medical details 
of the babies’ health, it was necessary to obtain the verbal permission of the 
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women to send a letter to their children’s health care providers. The letters were 
sent to the caller’s physicians (family physicians or pediatricians) for verification 
of the information obtained from the mothers. The doctors were asked to complete 
questionnaires and the state of general health of the babies as well as major and 
minor malformations. The follow-up procedures have been approved by Sick 
Children Hospital’s Research Ethics Committee. 
5.2.1.7. Statistical analysis.  
Outcome end points of interest were compared among those exposed to 
cetirizine in the first trimester group and control groups (not exposed to cetirizine 
and non-first trimester exposed to cetirizine) with the Student’s t test with 
Bonferroni correction, Chi-square or the Fisher’s exact test whenever suitable.  
5.2.2. Meta-analysis. 
A systematic review and meta-analyses were conducted on all observational 
cohort studies published (including the current cohort study) that address the effect 
of cetirizine on pregnancy outcomes and cohort studies that had hydroxyzine as an 
exposed group. Cetirizine is an active carboxylic acid metabolite of hydroxyzine 
(first generation antihistamine) [13]. Combining the extracted cetirizine studies and 
hydroxyzine studies in one meta-analysis is therefore biologically plausible and 
will increase the sample size to estimate the fetal safety of cetirizine and 
hydroxyzine during pregnancy.  
5.2.2.1. Search strategy.  
A systematic review was performed to retrieve all published articles 
involving cetirizine or hydroxyzine exposure during pregnancy. This review 
followed the guidelines of the Meta-Analysis of Observational Studies in 
Epidemiology (MOOSE) group [14]. Searches were conducted using electronic 
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databases for possibly relevant articles that were published in any language up to 
December 2012. Included databases were PubMed, SCOPUS, EMBASE and 
TOXLINE. The literature was searched using drug names (Cetirizine, Cetirizine 
Dihydrochloride, Zyrtec, Reactine, Zirtek, Voltric, Cetirizine AL, Hydroxyzine, 
Vistaril, Durrax or Atarax) and drug categories based on pharmacological action 
(Histamine H1 Antagonists, H1 Antihistaminic, H1 Receptor Blockaders, Non-
Sedating Histamine H1 Antagonists, Second Generation H1 Antagonists or first 
Generation H1 Antagonists).  
Subsequently, these terms were combined with various MeSH categories 
(including pregnancy, pregnancy complications, abnormalities, embryonic and 
fetal development, maternal exposure, teratogens) and keywords (including birth 
defect, abnormality, malformation, embryopathy). The reference lists of all 
retrieved studies, including reviews, were examined for articles not identified by 
the search strategy.   
5.2.2.2. Study selection.  
Studies were included in the meta-analysis if they met the following criteria: 
1- Observational cohort studies, but not case control, or case reports. 
2- Studies that reported the incidence of malformation and/or other pregnancy 
outcomes in the offspring of women who were or were not exposed to cetirizine 
during pregnancy (use of a control or comparison group). 
3- Sufficient data to calculate the Odd ratios. 
4- Reported data that was not included in a later report by the same group of 
investigators (to prevent duplication of overlapping reports). 
5- A sample size larger than 10. 
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6- Human studies only. 
Two authors reviewed the studies to determine whether or not they met 
inclusion criteria. 
5.2.2.3. Data extraction and analysis.  
A data extraction form was used to collect the information from each study. 
This information included: first author, year of publication, study design, study 
location, years of study and outcome measures. Outcome measures were extracted 
for either the cetirizine or hydroxyzine exposed group and the control group and 
these measures included the whole group number, live birth number, malformed 
cases, spontaneous and therapeutic abortion cases, and prematurity (< 37 weeks 
gestation) cases. All the data was arranged in 2x2 tables to calculate the odd ratios. 
A random-effects meta-analysis model was used to combine the risk data for 
malformation and other pregnancy outcomes by using a statistical program called 
Comprehensive Meta-Analysis Version 2.0. Odd rations and 95% confidence 
intervals were calculated. Heterogeneity of effects was assessed using the Q 
statistic. Three meta-analyses were conducted to assess the risk of major 
malformations, one for cetirizine studies, one for hydroxyzine studies, and another 
one for combined hydroxyzine and cetirizine studies. Two meta-analyses were 
performed for the other pregnancy outcomes (spontaneous abortion and 
prematurity). 
5.3. Results. 
5.3.1. Cetirizine cohort study.  
 The cohort study included 78 pregnancies exposed to cetirizine during the 
first trimester (with or without second or third exposure), 56 pregnancies exposed 
to cetirizine during second and/or third trimester (no first trimester exposure), and 
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134 pregnancies exposed to non teratogenic drugs. Mean of maternal age of the 
three groups were similar (between 32 and 33 years). 
 In the group exposed to cetirizine during first trimester, there were a total of 
73 live births counting three sets of twins, five spontaneous abortions, one 
therapeutic abortion, two fetal deaths, and eleven premature births. Two cases with 
major malformation were reported in the cetirizine first trimester exposed group: 
The first case was a child born with a hip dysplasia and the other case was Down’s 
syndrome, detected at 14 weeks and ending in therapeutic abortion at 18-19 weeks. 
Two cases with minor malformation were reported in the same group: 
periventricular leukomalacia was diagnosed in the same child that was born with a 
hip dysplasia, and the second case was a child born with a tongue tie. 
 In the group exposed to cetirizine during only the second and/or third 
trimester, there were 57 live births including one set of twins (all the pregnancies 
ended with a live birth), and four premature cases. There were no major 
malformations and one minor malformation. The child with the minor 
malformation was born with esophageal sphincter, which was not fully formed 
until 4-5 months. This defect runs in the paternal family. 
 In our control group, there were 128 live births including one set of twins, 
seven spontaneous abortions, and three premature cases. In this control group, 
there were three major malformations and one minor malformation. One of the 
major malformations was Trisomy 13 found in one of the spontaneously aborted 
fetuses. The other two major malformations were infants born with undescended 
testes associated with exstrophy of the bladder and right inguinal hernia. The minor 
malformation case was an infant born with an umbilical hernia. 
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 Two comparisons were made, one between the group exposed to cetirizine 
during first trimester and the control group (Table 5.1) and the other between the 
group exposed to cetirizine during the first trimester and the exposed group to 
cetirizine during second or third trimester (Table 5.2). There was no difference in 
the rates of major or minor malformation, live births, spontaneous or therapeutic 
abortions, still births, and rates of cesarean or neonatal distress among the groups. 
However, there were significant differences between the exposed group to 
cetirizine during first trimester and the control group in rates of prematurity (P = 
0.001), birth weight (P = 0.01) and gestational age at birth (P = 0.006). These 
differences were not detected between the group exposed to cetirizine in the first 
trimester and the group exposed to cetirizine during the second or third trimesters.  
Moreover, sub analysis revealed that offspring of women with asthma, twins and 
smoking cases receiving cetirizine exhibited significantly lower birth weights and 
rates of prematurity. After excluding them from the study group, these differences 
from the control group disappeared (Table 5.3). 
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Table 5.1. Outcomes of pregnancies in fetuses that had first Trimester 
cetirizine exposure and control group. 
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Outcome Cetirizine T1 group Control group P 
Live birth 73/81 128/135 0.27 
Spontaneous 
abortion 
5/81 7/135 0.77 
Therapeutic 
abortion 
1/81 0/135 0.38 
Stillbirth 2/81 0/135 0.14 
Major 
malformations a 
2/76 3/129b 1.00 
Minor 
malformations a 
2/76 1/128 0.61 
Birth weight, g c 3,317±704 3,547± 532 ˂ 0.01 
Gestational age c 39±2.56 40±1.59 ˂ 0.006 
Prematurity c 11/73 3/128 ˂ 0.001 
Cesarean section c 24/70 22/94 0.16 
Neonatal distress c 9/73 9/128 0.21 
 
a: Of live birth, therapeutic abortion and stillbirth. 
b: Of live birth, therapeutic abortion, stillbirth and one case of spontaneous abortion. 
c:Of live birth. 
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Table 5.2. Outcomes of pregnancies in fetuses that had first trimester 
cetirizine exposure and in fetus exposed to cetirizine during second and/or 
third trimester. 
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Outcome Cetirizine T1 group Cetirizine non T1 
group 
P 
Live birth 73/81 57/57 0.02 
Spontaneous 
abortion  
5/81 0/57 0.08 
Therapeutic abortion 1/81 0/57 1.00 
Stillbirth 2/81 0/57 0.51 
Major 
malformations a 
2/76 0/57 0.51 
Minor 
malformations a 
2/76 1/57 1.00 
Birth weight, g b 3,317±704 3,462±558 0.21 
Gestational age b 39±3 39±2 0.27 
Prematurity b 11/73 4/57 0.18 
Cesarean section b 24/70 16/56 0.57 
Neonatal distress b 9/73 11/57 0.33 
a: Of live birth, therapeutic abortion and stillbirth. 
b: Of live birth. 
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Table 5.3. Outcomes of pregnancies in fetuses that had first trimester 
cetirizine exposure and control group after removing of asthma, twins and 
smoking cases. 
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Outcome Cetirizine T1 Group Control Group P 
Live Birth 56/64 119/126 0.15 
Birth weight, g a 3,449±695 3,560±512 0.24 
Gestational age a 39±3 40±1 0.11 
Prematurity a 5/56 3/119 0.11 
a: Of live birth 
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5.3.2. Meta-analyses. 
 The electronic search identified 1500 literature titles. After removing all 
duplicates and reviewing titles and/or abstracts to exclude the animal studies, non-
cohort studies, review articles without original data, and articles that addressed 
pregnancy outcomes of antihistamines exposure other than cetirizine or 
hydroxyzine, twelve articles were reviewed in detail. Ten studies fulfilled the 
inclusion criteria for the meta-analysis including the current cohort study. The 
other four were excluded because one of them had no healthy control groups [15], 
one was a case control study [16], one study focused only on one type of 
malformation [17], and one study was published only as an abstract [18] and the 
same data were included in a peer reviewed publication [9] (Figure 5.1).  
 Of the ten studies included in our meta-analyses, four studies included 
women on hydroxyzine [19, 20, 21, 22], four studies were on cetirizine [10, 23, 24] 
and two studies were on hydroxyzine and cetirizine [9, 25] (Table 5.4). All the 
included studies measured the risk of major malformations, whereas five studies 
assessed the risk of spontaneous abortion [19, 9, 24, 10, current study], and two 
studies also assessed prematurity [10, current study]. The Q-statistic for 
heterogeneity of effects was not significant for any of the analyses (P > 0.05).  
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Figure 5.1. Diagram for search strategy and study selection for the meta-
analyses. 
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Relevant references identified from electronic databases, 
search performed using cetirizine, hydroxyzine or 
antihistamine (and related terms) and combined with all 
terms related to pregnancy outcomes (n = 1050). 
References excluded after 
screening titles and/or abstracts: 
duplicate, animal studies, non- 
cohort studies, not include 
interested drugs or review articles 
(n = 1039).  
  
 
(n= )  13 publications reviewed for a detailed 
evaluation. 11 from electronic search 
and 2 from reference lists. 
4 references excluded: no control 
groups, case control study, reported 
one kind of malformations or the 
same data was included in a high 
quality publication. 
Current cetirizine 
cohort study included.  
10 studies included in 
the meta-analysis. 
4 studies on 
hydroxyzine. 
4 studies on 
cetirizine. 
2 studies on hydroxyzine 
and cetirizine. 
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Table 5.4. Characteristics of the nine studies included in the meta-analyses. 
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Study name 
(year) 
Medication 
name 
No. of 
exposed 
No. of 
controls 
Pregnancy 
outcome 
evaluated 
Publication type 
Erez (1971) 
[19] 
Hydroxyzine 79 36 Malformed, 
SA 
Peer review journal 
Heinonen 
(1977) [21] 
Hydroxyzine 50 50,232 Malformed Book 
Briggs (1994) 
[20] 
Hydroxyzine 828 228,273 Malformed Book (personal 
communication), 
control group 
published by Schatz 
& Petitti  
Schatz (1997) 
[25] 
Hydroxyzine, 
cetirizine 
76 82 Malformed Guest editorial 
Einarson 
(1997) [9] 
Hydroxyzine, 
cetirizine 
92 92 Malformed, 
SA 
Peer review journal 
Kallen (2002) 
[23] 
cetirizine 917 402,628 Malformed Peer review journal 
Diav-Citrin 
(2003) [22] 
Hydroxyzine 33 844 Malformed Peer review journal 
Paulus (2004) 
[24] 
cetirizine 123 470 Malformed, 
SA 
Abstract  
Weber (2008) 
[10] 
cetirizine 177 1,521 Malformed, 
SA, P 
Peer review journal 
Current study Cetirizine 76 129 Malformed, 
SA, P 
Peer review journal 
SA: Spontaneous Abortion, P: Prematurity 
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5.3.2.1. Meta-analysis of hydroxyzine studies that assessed the risk of major 
malformations. 
 Data from six studies with a total of 1,082 women exposed to hydroxyzine 
and 279,480 unexposed controls were included in the meta-analysis. The risk for 
congenital malformations in the offspring of women exposed to hydroxyzine was 
not higher than those in the controls that were not exposed to hydroxyzine (OR 
1.21; 95% CI 0.92-1.59) (Figure 5.2). 
5.3.2.2 Meta-analysis of cetirizine studies that assessed the risk of major 
malformations. 
 Six potentially relevant cetirizine studies fulfilled the inclusion criteria for 
the meta-analysis, two of which were excluded because they reported two zero 
events in the exposed and in the control groups (odd ratio could not be calculated 
from these studies) [9, 25]. A total of 1,293 exposed and 404,748 unexposed 
controls from the remaining four studies were included in the meta-analysis. The 
odds ratio (95% CI) for incidence of abnormalities after exposure to cetirizine was 
1.26 (0.93-1.69) (Figure 5.3).  
5.3.2.3. Meta-analysis of combined hydroxyzine and cetirizine studies that 
assessed the risk of major malformations. 
 This meta-analysis combined all hydroxyzine and cetirizine studies, with a 
total of 2,448 exposed and 684,305 unexposed controls. The odds ratio (95% CI) 
for incidence of abnormalities after exposure to hydroxyzine or cetirizine was 1.23 
(1.01-1.51), which was marginally significant (Figure 5.4).  
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5.3.2.4. Meta-analysis of hydroxyzine and cetirizine studies that assessed the 
risk of spontaneous abortion. 
 Five studies examined the risk of spontaneous abortion for pregnant women 
exposed to hydroxyzine or cetirizine, and were included in the meta-analysis (total 
of 598 exposed and 2,491 unexposed controls). The odd ratio (95% CI) for 
incidence of spontaneous abortion after exposure to hydroxyzine or cetirizine was 
1.09 (0.77-1.53). (Figure 5.5).  
5.3.2.5 Meta-analysis of cetirizine studies that assessed the risk of 
prematurity. 
 Only two studies reported prematurity in the cetirizine- exposed and control 
groups, including the current cohort study and there were no hydroxyzine studies 
that examined the risk of prematurity (total of 233 exposed and 1,640 unexposed 
controls). The odd ratio (95% CI) for incidence of prematurity after exposure to 
cetirizine was 1.47 (0.31-7.01) (Figure 5.6).  
  
53 
 
 
 
 
 
 
 
 
Figure 5.2. Odds ratios and 95% confidence intervals for malformations in 
offspring of women using hydroxyzine during pregnancy versus control 
groups. 
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Test of heterogeneity: P-value = 0.808  
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Figure 5.3. Odds ratios and 95% confidence intervals for malformations in 
offspring of women using cetirizine during pregnancy versus control groups. 
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Test of heterogeneity: P-value = 0.984  
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Figure 5.4. Odds ratios and 95% confidence intervals for malformations in 
offspring of women using hydroxyzine or cetirizine during pregnancy versus 
control groups. 
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Test of heterogeneity: P-value = 0.981  
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Figure 5.5. Odds ratios and 95% confidence intervals for spontaneous 
abortion for women using hydroxyzine or cetirizine during pregnancy versus 
control groups. 
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Test of heterogeneity: P-value = 0.886  
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Figure 5.6. Odd ratios and 95% confident intervals for prematurity in 
offspring of women using cetirizine during pregnancy versus control groups. 
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Test of heterogeneity: P-value = 0.050  
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5.4. Discussion. 
5.4.1. Cetirizine cohort study. 
 The results of our controlled cohort study suggest that this antihistamine, 
when taken during organogenesis, is not associated with an increased risk of major 
malformations or spontaneous abortions when compared to non teratogenic 
medications taken by healthy pregnant women. Importantly, this association was 
also not present when compared to disease- matched women who took cetirizine 
after the organogenesis period. These results agree with several other human 
studies, that there is no risk above the baseline for major malformations when 
cetirizine is taken during pregnancy [9, 10]. 
There were statistically significant differences between the first trimester 
(T1) exposed group and the control group in the rate of twins (P = 0.03) and 
maternal asthma (P = 0.0007). These two confounders are strongly associated with 
prematurity [26, 27]. The control group was not matched for smoking, and 
smoking is also a known cause of prematurity [28]. We analyzed the data after 
removing these confounders and examined whether the association between 
cetirizine exposure during organogenesis and prematurity is still evident. After 
removing all twins, asthma and smoking cases from both groups, the association 
between cetirizine and prematurity (P = 0.11), birth weight (P = 0.24), and 
gestational age at birth (P = 0.11) disappeared (Table 5.3). Just as important, the 
association between prematurity and cetirizine use during the first trimester is not 
present when we compared it with a disease –match group. These data highlight 
the importance of controlling for confounding by indication in pregnancy outcome 
studies.  
Our cohort study has limited power to show increased teratogenic risk. 
Approximately 200 cases and an equal number of matched comparisons are needed 
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to detect (with a power of 80% and a =0.05) a five- fold increased teratogenic risk 
above the baseline of 3%. To overcome this hurdle, we increased the sample size 
by combining the previous human studies in one meta-analysis and estimated the 
major malformations and other pregnancy outcomes. 
5.4.2. Meta-analyses. 
 The meta-analyses suggest that the use of hydroxyzine or cetirizine does not 
appear to be associated with a major increased risk for malformations. Although 
the meta-analysis combining hydroxyzine and cetirizine studies shows a marginal 
association of an increased risk for major malformation (odd ratio 1.31; 95% CI 
1.01-1.51), this result may not be clinically significant. In particular, as shown in 
our cohort study, there may be confounding by indication, as several studies 
suggested an increased risk of malformation in offspring of asthmatic patients. 
These results were compatible with a case control study published in 2009 
[16] that looked at the association between birth defects and antihistamine use 
during early pregnancy. Moreover, a non-interventional observational cohort study 
published in 1998 [15] followed women who were exposed to newly marketed 
drugs at that time, one of them being cetirizine. The results showed that the 
proportion of live infants with a congenital abnormality born to mothers exposed to 
newly marketed drugs in the first trimester was similar to the percentage of 
congenital anomalies in the general population (no congenital cases reported after 
cetirizine exposure).  
Furthermore, secondary analyses of other pregnancy outcomes showed no 
apparent increased risk for spontaneous abortions , prematurity or after exposure to 
cetirizine or hydroxyzine. 
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5.5. Conclusion. 
In conclusion, based on the current cohort study and meta-analysis, 
cetirizine is not associated with an increased risk of major malformations or other 
adverse fetal outcomes. The study highlights the importance of control for 
confounding by indication, in this case asthma, which may adversely affect 
pregnancy outcomes irrespective of cetirizine use. 
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6.1. Introduction. 
Antihistamines (AHs) are among the most commonly prescribed drugs 
during pregnancy, with approximately 15% of pregnant women reporting the use 
of over-the-counter or prescribed AHs at some point during their pregnancy, 
particularly during the first trimester [1-3]. AHs are classified as either H1 or H2 
with reference to the relative selectivity of their targeting receptor. H1-AHs are 
used for the treatment of nausea and vomiting during pregnancy (NVP), which 
occurs in approximately 85% of pregnancies as well as for the symptomatic relief 
of asthma, urticaria, allergy, the common cold, and other relatively minor 
conditions [4, 5]. H2-AHs are used to treat indigestion and acid reflux [6]. H1-AH 
exposure typically occurs most commonly during the first trimester, while H2-AH 
exposure is more common thereafter as NVP tends to present during the first 
trimester and resolve in the early second trimester and gastric symptoms usually 
appear later in pregnancy [7]. Given the large number of pregnant women exposed 
to H1-AHs during the first trimester - a critical time for fetal development - there is 
a compelling need to examine any potential risks arising from their use during 
pregnancy.  
The gold standard of clinical research is the double blind randomized 
placebo control trial. Unfortunately, this approach is ethically unacceptable when 
studying drug safety in pregnancy due to the possibility of exposing pregnant 
mothers and their unborn babies to potentially harmful treatments [8]. 
Consequently, the most practical approach to quantify the safety and risks of H1-
AH exposure during the first trimester is to conduct a systematic review and meta-
analysis of all available observational cohort and case control studies of exposed 
mothers [9]. Previous research on the safety of H1-AH use during pregnancy does 
exist in the form of meta-analyses. Unfortunately the information from these 
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studies is contradictory, outdated or specific to one type of H1-AH, leaving 
questions surrounding the safety of all available H1-AHs.  
The first meta-analysis conducted over 20 years ago included all the studies 
available at that time and concluded that H1-AHs can safely be used during 
pregnancy [10]. However, upon re-analysis of all this data, a second group 
produced contradictory results with respect to the cohort studies meta-analysis, in 
which they showed an increased risk of major malformation in those exposed to 
H1-AHs. The same study demonstrated no increased risk when analyzing case 
control studies or the studies that focused only on doxylamine [11]. Other studies 
have included meta-analyses on doxylamine when used for treatment of NVP [12-
14], loratidine, hydroxyzine, and cetirizine [15, 16], each generating reassuring 
results. The primary objective of the present study is to determine whether H1-
AHs, used in the treatment of any condition during the first trimester of pregnancy, 
are associated with an increased rate of major malformation. Secondary objectives 
include assessing the safety of H1-AHs used specifically for the treatment of NVP 
as well as examining the effect of H1-AHs on other pregnancy outcomes, including 
spontaneous abortions, prematurity, stillbirth, and low birth weight, following first 
trimester exposure.  
6.2. Methods. 
A systematic review and meta-analyses were conducted on all observational 
cohort and case control studies published that addressed the effect of H1-AH on 
pregnancy outcomes.  
6.2.1. Search strategy.  
Following the guidelines of PRISMA [17], a systematic review was 
performed to retrieve all published articles involving H1-AH exposure during 
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pregnancy. Electronic databases including PubMed and EMBASE were searched 
from inception  till 10 January 2016 for relevant articles published in any language. 
Search strategies are presented in Appendix 5. Subsequently, the reference lists of 
all collected studies were reviewed for articles not previously identified by the 
search strategy.  
6.2.2. Study selection.  
Any published human study that met the following criteria was included in 
the meta-analyses: 
1- Observational cohort or case control studies that clearly confirmed in the 
original article the exposure to H1-AH during first trimester and those studies that 
had enough data to select the group that had first trimester exposure.  
2- Studies that  had sufficient data to select only major malformation and/or other 
pregnancy outcomes in the offspring of women who were exposed to one or more 
types of H1-AH during the first trimester of pregnancy and were compared to a 
control group, where the control consisted of women who were not exposed to any 
drug throughout their entire pregnancy and/or women who were exposed to drugs 
other than specific H1-AHs under study. 
3- Studies that provided sufficient data to calculate the odds ratios (ORs) and the 
95% confidence intervals (95% CI). 
4- Studies with a sample size larger than 10.  
5- Studies that focused only on medications used for therapeutic purposes. 
6- Updated studies by the same group of investigators on the same type of H1-AHs 
were selected to prevent duplication of overlapping reports. 
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Two authors (FE and MJR) screened the titles and abstracts of all studies 
identified by the electronic search to determine whether or not they met inclusion 
criteria to evaluate the full text.  Full text of likely studies for eligibility was 
reviewed by the two authors (FE and LHF). Disagreements were resolved by a 
third author (GK). 
6.2.3. Data extraction. 
Information from each study was collected with the use of a data extraction 
form (Appendix 6). Information collected included the drug name of H1-AH , first 
author, year of publication, journal name, study design, study location, year of 
study, whether exposure occurred during the first trimester, type of control, and 
outcome measures.  
Outcome measures were extracted for both the exposed and control groups 
and included a number of the following: pregnant women, live births, major 
malformations (any structural defect that caused significant medical, surgical, or 
cosmetic problems) [18], preterm infants (infants born alive before 37 weeks’ 
gestation), spontaneous abortions (miscarriage; loss of pregnancy before 20 weeks’ 
gestation), stillbirths (fetal death after 20 weeks ’ gestation), and low birth weight 
infants (live born infants of less than 2,500 g (5 pounds 8 ounces))[19]. The 
original studies must have used the same terminology for the outcome measures 
and/or its definitions in order to be included. Also, if detailed information about 
malformation was reported in the original study, screening of the major 
malformation was performed. Authors of included studies were not contacted to 
obtain data not reported in their original publication. 
All the data were arranged in 2x2 tables to calculate the ORs and 95% CI 
and all the outcomes were considered binary outcomes (the adverse outcomes had 
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two possible outcomes: all or nothing). When calculating ratios for spontaneous 
abortions, as well as for stillbirth, the denominator was the total number of 
pregnancies. For prematurity, low birth weight, and major malformation outcomes, 
ratios were calculated using live birth when this information was available. 
Stillbirths, elective, therapeutic and/or spontaneous abortions that were diagnosed 
as major malformations were all counted as major malformation cases.  
6.2.4. Data analysis.  
Risk data for malformation and other pregnancy outcomes collected in all 
studies was combined with the Comprehensive Meta-Analysis Version 2.0, using a 
random-effects model. Both odds ratios and 95% confidence intervals were 
calculated for each outcome. Heterogeneity among studies was assessed using the 
Q statistic, which was then quantified by I2. A significant Q statistic (P<0.05), 
represents a high degree of variance among the studies analyzed. An associated I2 
value between 0% to 40% might not be important, while between 30% to 60% may 
represent moderate heterogeneity, between 50% to 90% may represent substantial 
heterogeneity, and between 75% to 100% considerable heterogeneity [20]. Four 
separate meta-analyses were conducted to assess the risk of major malformations:  
1) All H1-AH exposed cohort studies. 
2) Sensitivity analysis of H1-AH cohort studies excluding studies where the 
comparison group may have had some H1-AH exposure other than the drug under 
investigation. 
3) H1-AHs only used for NVP.  
4) All H1-AH case control studies. 
74 
 
Four separate meta-analyses were performed for all other collected pregnancy 
outcomes (prematurity, spontaneous abortion, stillbirth, and low birth weight). 
6.2.5. Analysis of potential publication bias. 
Funnel plots were generated using the Duval and Tweedie’s trim and fill 
method for each meta-analysis where the number of studies included was greater 
than 10. Funnel plots were visually inspected in order to assess for publication 
bias. The number of unpublished studies (K) that were potentially omitted from the 
primary analysis was determined; if evidence of publication bias existed (K>0), 
adjusted point estimates (ORs) were calculated based on the number of omitted 
studies [21]. 
6.2.6. Quality assessment. 
The Newcastle-Ottawa assessment scale for cohort studies and case control 
studies was used to evaluate the quality of included studies in the meta-analyses 
[22]. The evaluation focused on the following three categories:  the selection 
category ranged from 0–4 points, the comparability category ranged from 0–2 
points, and the outcome category ranged from 0–3 points (the outcome category 
was for cohort studies and for case control studies was called the exposure 
category). The scale range was from 0 to 9. For the comparability category, 
controlling for maternal age was the most important factor, as studies were given 1 
point for this factor and if any other factors such as nicotine consumption, drinking 
alcohol, diabetes, hypertension, previous abortions and/or previous malformed 
children were controlled for, they received 2 points. For the outcome category for 
the cohort studies, the follow up period for major malformation had to be at least 6 
months. 
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6.3. Results.  
An electronic search of all databases identified a total of 1724 manuscripts 
(Figure 6.1). After removing all duplicate publications and excluding animal 
studies, and studies on drug effectiveness, 342 articles were reviewed in detail. A 
total of 37 studies (33 cohort studies [7, 16, 23-52] and 4 case control studies [3, 
53-55] fulfilled the inclusion criteria for the meta-analysis (Table 6 for 
characteristics of the included studies (Appendix 7)).  
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Figure 6.1. Flow chart for study selection for the meta-analyses. 
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The average quality score of the included studies was 6.08 (± 1.95 (SD)) out 
of 9 according to the Newcastle-Ottawa assessment scale. All the included studies 
assessed major malformations or major malformation plus other pregnancy 
outcomes, except one cohort study that did not assess major malformations but 
rather spontaneous abortions and prematurity [7]. 
6.3.1. Meta-analysis of cohort studies assessing risk of major malformations. 
Data from 32 cohort studies [16, 23-52] with a total of 49,635 women 
exposed to H1-AH and 1,302,596 unexposed controls were included in this meta-
analysis. The risk of major malformation in the offspring of women exposed to 
H1-AHs was not higher than that of the control population (OR 1.07; 95% CI 0.98-
1.16) (Figure 6.2). The Q-statistic for heterogeneity of effects was not significant 
(P > 0.05, I2 < 25%) and there was no evidence of publication bias in this analysis 
(Figure 6.3). 
6.3.2. Sensitivity analysis of the meta-analysis of cohort studies assessing risk 
of major malformations. 
Four cohort studies were excluded [30, 32, 41, 45], since exposure of the 
control group to an H1-AH not under investigation could not be ruled out for these 
studies. For example, specific H1-AHs were being studied and compared to a 
control group, which may have been exposed to antiemetic drugs that have H1-
AHs such as doxylamine. The remaining 28 cohort studies [16, 23-29, 31, 33-40, 
42-44, 46-52] with a total of 21,427 women exposed to H1-AHs and 449,939 
unexposed controls were included in the sensitivity analysis. The risk of major 
malformation in the offspring of women exposed to H1-AHs was not higher than 
that of the control groups (OR 1.01; 95% CI 0.90-1.12) (Figure 6.4). The Q-
statistic for heterogeneity of effects was not significant (P > 0.05, I2 = 0%) and 
there was no evidence of publication bias in this analysis. 
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6.3.3. Meta-analysis of cohort studies assessing risk of major malformations 
for H1-AHs used to treat NVP. 
There were 18 cohort studies [23-29, 31, 33-37, 44, 46, 50, 52] that studied 
H1-AHs as an antiemetic. A total of 27,243 women who were exposed to H1-AHs 
for treatment of NVP and 441,623 unexposed controls were included in this meta-
analysis. The risk of major malformation in the offspring of women exposed to 
H1-AHs when used for the treatment of NVP was not higher than the control group 
(OR 0.95; 95% CI 0.87-1.05) (Figure 6.5). There was no indication of difference in 
risk of major malformations in the offspring of women exposed to H1-AHs 
compared to control. The Q-statistic for heterogeneity of effects was not significant 
(P > 0.05, I2 = 0%) and there was no evidence of publication bias in this analysis. 
6.3.4. Meta-analysis for case control studies assessing risk of major 
malformations. 
Four case control studies [3, 53-55] fulfilled the inclusion criteria; a total of 
7,270 women exposed to H1-AHs and 90,336 unexposed controls were included in 
the meta-analysis. The risk of major malformation in the offspring of women 
exposed to H1-AHs was not higher than that of the control group (OR 1.05; 95% 
CI 0.90-1.23) (Figure 6.6). The Q-statistic for heterogeneity of effects was not 
significant (P > 0.05, I2 = 0%). 
6.3.5. Meta-analysis of cohort studies assessing the risk of prematurity. 
Nine cohort studies reported prematurity outcomes [7, 16, 29, 42-44, 47, 51, 
52] for a total of 1,799 H1-AHs exposed women and 9,156 unexposed controls. 
The odds ratio (95% CI) for the incidence of prematurity after exposure to H1-AHs 
was 0.96 (0.76-1.20). The Q-statistic for heterogeneity of effects was not 
significant (P > 0.05) with the I2 value was between 25%-50% which indicates low 
heterogeneity (Figure 6.7).  
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6.3.6. Meta-analysis of cohort studies assessing the risk of spontaneous 
abortion. 
Thirteen cohort studies reported spontaneous abortion outcomes [7, 16, 23, 
27, 39, 40, 42, 47-52] for a total of 2,522 H1-AH exposed women and 7,276 
unexposed controls. The odds ratio (95% CI) for the incidence of spontaneous 
abortion after exposure to H1-AHs was 1.00 (0.83-1.20) (Figure 6.8). The Q-
statistic for heterogeneity of effects was not significant (P > 0.05, I2 = 0%), and 
there was no evidence of publication bias in this analysis. 
6.3.7. Meta-analysis of cohort studies assessing the risk of stillbirth. 
Eight cohort studies reported stillbirth outcomes [7, 16, 23, 39, 40, 43, 48, 
50] for a total of 1,571 H1-AH exposed women and 3,328 unexposed controls. The 
odds ratio (95% CI) for the incidence of stillbirth after exposure to H1-AHs was 
1.23 (0.48-3.18). The Q-statistic for heterogeneity of effects was not significant (P 
> 0.05, I2 < 25%) (Figure 6.9).  
6.3.8. Meta-analysis of cohort studies assessing the risk of low birth weight. 
Three cohort studies reported low birth weight outcomes [43, 50, 52] for a 
total of 265 H1-AH exposed women and 384 unexposed controls. The odds ratio 
(95% CI) for the incidence of low birth weight after exposure to H1-AHs was 1.20 
(0.63-2.29). The Q-statistic for heterogeneity of effects was not significant (P > 
0.05, I2 = 0%) (Figure 6.10). 
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Figure 6.2. Forest plots of all H1-AHs cohort studies that assessed the risk of 
major malformations. 
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Total odds ratio (95% CI) = 1.07 (0.98- 1.16) 
Test of heterogeneity: Q = 40.35, df = 31 (P = 0.12), I2 = 23.16% 
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Figure 6.3. Publication bias using funnel plot for meta-analysis of all H1-AHs 
cohort studies that assessed the risk of major malformations. 
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Open circles represent the included studies, the open rhombus is the observed measure of effect, and the closed 
rhombus is the adjusted measure of effect. 
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Figure 6.4. Forest plots of H1-AHs cohort studies excluding the studies that 
the comparison group may have some H1-AHs exposure that assessed the risk 
of major malformations (sensitivity analysis). 
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Total odds ratio (95% CI) = 1.01 (0.90- 1.12) 
Test of heterogeneity: Q = 11.19, df = 27 (P = 1.00), I2 = 0.00% 
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Figure 6.5. Forest plots of H1-AHs used to treat NVP cohort studies that 
assessed the risk of major malformations. 
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Total odds ratio (95% CI) = 0.95 (0.87- 1.05) 
Test of heterogeneity: Q = 8.42, df = 17 (P = 0.96), I2= 0.00% 
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Figure 6.6. Forest plots of H1-AHs case control studies that assessed the risk 
of major malformations. 
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Total odds ratio (95% CI) = 1.05 (0.90- 1.23) 
Test of heterogeneity: Q = 21.01, df = 3 (P = 1.00), I2 = 0.00% 
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Figure 6.7. Forest plots of H1-AHs cohort studies that assessed the risk of 
prematurity. 
  
92 
 
 
 
 
 
 
 
 
 
 
Total odds ratio (95% CI) = 0.96 (0.76- 1.20) 
Test of heterogeneity: Q = 13.64, df = 8 (P = 0.09), I2 = 41.36% 
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Figure 6.8. Forest plots of H1-AHs cohort studies that assessed the risk of 
spontaneous abortion. 
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Total odds ratio (95% CI) = 1.00 (0.83- 1.20) 
Test of heterogeneity: Q = 10.93, df = 12 (P = 0.54), I2 = 0.00% 
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Figure 6.9. Forest plots of H1-AHs cohort studies that assessed the risk of 
stillbirth. 
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Total odds ratio (95% CI) = 1.23 (0.48- 3.18) 
Test of heterogeneity: Q = 8.05, df = 7 (P = 0.33), I2 = 13.09% 
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Figure 6.10. Forest plots of H1-AHs cohort studies that assessed the risk of 
low birth weight 
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Total odds ratio (95% CI) = 1.20 (0.63- 2.29) 
Test of heterogeneity: Q = 1.81, df = 2 (P = 0.41), I2 = 0.00% 
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6.4. Discussion. 
This study provides a quantitative estimate of the risk of adverse pregnancy 
outcomes following first trimester exposure to H1-AHs. The study of H1-AHs in 
pregnancy, which includes developing a clear picture of the safety and possible 
risks associated with their use, is important given their wide use by pregnant 
women. As a consequence of being available both over the counter and as a 
prescription medication, intentional and accidental exposures are frequent in the 
first and subsequent trimesters. To date, the majority of research on H1-AH 
exposure in pregnancy has been reassuring, providing evidence suggesting there is 
no increased risk associated with their use. Some conflicting studies, however, do 
exist, including several original research studies and one meta-analysis [11]. This 
highlights the need for an up-to-date review and analysis of H1-AH safety in 
pregnancy that includes all new available research studies as well as those 
previously reviewed.  
Four different meta-analyses were conducted by us to address the potential 
effects of H1-AHs with respect to major malformations. As we collected studies 
with two different designs, cohort and case control, meta-analyses were conducted 
separately for each type. 
The first meta-analysis included all 32 available cohort studies, which met 
the study inclusion criteria. The results of this meta-analysis contradict the most 
recently published meta-analysis on H1-AH safety based on cohort studies, 
published in 2014 by Chin et al. [11]. However, this particular meta-analysis 
included only 11 studies compared to our 33, with their most recent study being in 
1993 [38] whereas ours being in 2014 [16] The lack of randomized studies on H1-
AH in pregnancy, similar to lack of randomized studies of virtually all drug classes 
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in pregnancy, increases the risk of bias and hence, the need to carefully assess such 
potential bias.  
Of potential importance, given our inclusion criteria, there were three studies 
which were excluded from our analysis but whose results add to the H1-AH safety 
profile [56-58]. In these studies H1-AH use was not therapeutic but rather as an 
overdose or abuse. The results of these studies that showed no association between 
H1-AH use and major malformation are important as the exposure of these 
pregnant women was to much higher doses than what would have been 
experienced in therapeutic use. These findings further corroborate our hypothesis 
that H1-AHs are not teratogenic.  
Following our analysis of all 32 cohort studies, we performed sensitivity 
analyses, trying to address some potential bias, by excluding those studies where 
members of the control group might have been exposed to an H1-AH other than 
the drug under investigation. As an example, if meclizine safety was being 
assessed and compared to a group of women not exposed to meclizine (but where 
they could have been exposed to drugs other than meclizine such as doxylamine), 
we could not ascertain that women in the control group were not exposed to a 
different H1-AH, unless clearly stated by the authors. While still able to provide us 
with some safety information, this was not an ideal control group for our analysis. 
The results of our sensitivity analysis were consistent with the original analysis 
where no association between H1-AH use and major malformation was found. 
We have also carried out a separate analysis looking at studies where H1-
AHs were used to treat NVP. A total 18 of our 32 cohort studies looked 
specifically at H1-AH used for the treatment of NVP. The results showed no 
increase in the risk of major malformations in the offspring of women exposed to 
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H1-AHs used to treat NVP compared to control. There is ample evidence that NVP 
renders protective effects on pregnancy outcome, with mothers who experience 
morning sickness having better birth outcomes, including reduced risks of 
spontaneous abortion, preterm birth, malformation, and children with higher IQ 
[59]. Our analysis for this potential bias by indication ruled out a significant bias. 
Four case control studies met the inclusion criteria and were included in this 
meta-analysis. Although there were many additional case control studies available 
in the literature, they could not be included in our meta-analysis since they each 
assessed the risk of only one type of malformation. The results of the case control 
study analysis did not show an increase in risk of major malformation following 
H1-AHs use. Since, the meta-analyses for cohort studies and case control studies 
conducted in this current study cannot rule out an increased risk for specific 
congenital anomalies, this limitation should be addressed in future research.  
To our knowledge, this is the first meta-analysis addressing pregnancy 
outcomes other than major malformations, following exposure to any H1-
antihisimines. These included the potential effect of H1-AHs on prematurity, 
spontaneous abortion, low birth weight and stillbirth.  
In looking at prematurity, nine cohort studies were available with outcomes. 
Individually all nine studies showed no increase in the risk of prematurity 
following H1-AH exposure and therefore, as expected, the combined results of the 
meta-analysis also found no increased risk for prematurity.  
When evaluating the effects of H1-AH on spontaneous abortion, 13 studies 
were available with outcomes and included in the meta-analysis. Individually and 
combined, these studies showed no increased risk of spontaneous abortion 
following H1-AHs exposure. Importantly, results of the initial analysis 
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demonstrated evidence of publication bias that required adjusting the overall 
estimate to overcome the presence of bias. After the adjustment, the overall result 
did not change, indicating there is no increased risk of spontaneous abortion 
associated with H1-AH use. This particular meta-analysis is important because 
animal models assessing the safety of H1-AHs during pregnancy have suggested 
that they may negatively impact the implantation process [60]. Reassuringly, this 
meta-analysis shows no increased risk of spontaneous abortion following 
therapeutic use of this medication.  
Eight cohort studies assessed stillbirth following H1-AH exposure. The eight 
studies both individually and when combined showed no increase in the risk of 
stillbirth between exposed and control groups. Since the original studies did not 
examine the cause of stillbirth in these groups, we cannot rule out the association 
between the H1-AH use and stillbirth outcome. 
Three studies assessed low birth weight, not showing increased risk. Low 
birth weight is caused either by preterm birth or by stunted growth for gestational 
age, or a combination of both. Being small for gestational age can be due to 
intrauterine growth restriction secondary to many possible factors [61]. There is a 
lack of data in the original studies as for the causes of low birth weight, and more 
studies will be needed to draw firm conclusions.  
The available studies, none of which is randomized, performed over half a 
century should increase one’s vigilance for potential sources of bias. Only about 
half of the included studies controlled for maternal age and/or other confounders 
such as nicotine and alcohol consumption, previous abortions, diabetes, gravidity 
and/or parity [3, 7, 16, 25, 37-40, 43, 44, 46, 48, 50, 52, 54, 55]. However, their 
results are not distinctively different from those which controlled for these 
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variables. Two included studies measured H1-AHS use during the first trimester as 
prescriptions filled, without any assurance that the pregnant women actually took 
the medications [33, 42]. Eleven studies were conducted in teratology information 
services [16, 38-40, 43, 44-52]. This can potentially introduce a selection bias as 
there is evidence demonstrating that pregnant women of low socioeconomic class 
do not use such services with the same frequency as women of higher 
socioeconomic status and thus the study population may not be generalizable [62]. 
Data collected from different studies may be subjected to bias as different studies 
had different reporting standards and different classifications of the outcome.  
However, each included study utilized the same standards for its cases and control 
groups, so that the estimated risk in each study may not be affected. There are also 
sources of potential bias by indication. NVP has been shown to confer more 
favorable pregnancy outcome. As shown above, we have addressed this potential 
source of bias by analyzing separately only the studies where AH were given for 
morning sickness, and this analysis does not suggest an apparent bias in overall 
malformation rates. Similarly, AH are sometimes used for the allergic component 
of asthma among women, and here a bias against the null hypothesis may be 
created by less favorable pregnancy outcome in asthmatic women [63]. However, 
available studies did not specify asthma as a diagnosis and hence this potential 
source of bias cannot be ruled out. 
6.5. Conclusion. 
In conclusion, based on our updated meta-analyses, with very large sample 
sizes, H1-AHs do not appear to be associated with an increased risk of major 
malformation or other adverse fetal outcomes. Despite methodological limitations 
and potential sources of unresolved bias, this study may provide important 
information to both pregnant women and their health care providers regarding the 
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safety of H1-AH use during early pregnancy. At the present time, these meta-
analyses cannot rule out an increased risk for specific congenital malformations. 
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Chapter 7: When original positive studies of novel therapies are subsequently 
nullified; cumulative meta-analyses in preeclampsia. 
This chapter has been published previously: 
Etwel F, Koren G. When positive studies of novel therapies are subsequently 
nullified: cumulative meta-analyses in preeclampsia. Clin Invest Med. 2015 Oct 
7;38(5):E274-83. 
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7.1. Introduction. 
Typically, after laboratory and experimental animal investigations, novel 
therapeutic modalities are introduced to humans through case reports and small 
non-randomized, prospective studies. These are subsequently followed by 
randomized, double blinded, placebo controlled trials (RCTs), which eventually 
allow researchers to define whether the modality is sufficiently effective and safe 
over an existing gold standard. The lag time between the first published RCT and a 
decision by the medical and scientific communities to accept or reject a new 
modality, can be relatively long. During this period, scientific communications 
through editorials, commentaries, letters to editors and lectures, are vehicles that 
may convince clinicians to use or not to use the new treatment. 
In the area of maternal-fetal medicine, new therapeutic options are few and 
far between [1]. The ethical challenge of exposing a developing fetus to drugs can 
cause delays and hesitations among clinicians and drug companies alike. Yet, not 
treating serious maternal conditions can also adversely affects the unborn child and 
puts the pregnant patient at risk of morbidity and mortality[2]. 
Usually, when clinician-investigators complete an RCT of a novel modality, 
they attempt to publish the results in high citation impact journals, as these assure 
wide professional and public dissemination, in addition to increased likelihood of 
future grant funding and professional promotion [3]. However, in more than a few 
cases, the first, high impact factor publications suggesting a significantly favorable 
effect had been followed by negative trials.  
The objective of the present study was to examine changes over time in the 
pooled effect size of RCT published on the protective effects of antioxidants and 
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low dose aspirin against preeclampsia, a common and serious obstetric 
complication [4], and identify determinants that may affect these changes. 
7.2. Methods. 
We used two recently published meta-analyses of RCTs examining the 
protective effects of antioxidant treatment and those of low dose aspirin against 
preeclampsia [5-6]. The two selected meta-analyses were subjected to 
methodological quality assessment using the AMSTAR method [7]. The 
assessment of multiple systematic reviews' (AMSTAR) is a tool containing an 11 
point questionnaire with each point having four possible answers. The AMSTAR 
quality assessment tool falls into three ranges, High (9-11), Medium (5-8), and 
Low (0-4) [8]. The quality assessment was applied to the studies in the original 
meta-analyses to ensure that the studies selected were of good quality and their 
analyses included appropriate inclusion and exclusion criteria to avoid clinical and 
methodological heterogeneity and to control for internal validity.  
In both meta-analyses, some papers were “positive” in terms of protective 
effect (defined by us as RR below 0.9) (RR of 0.9 suggests a 10% protective effect 
which was considered by us a reasonable minimum) and some were negative (RR 
equal or above 0.9). The overall result of the antioxidant meta-analysis was “no 
protective effect” (negative). In the meta-analysis of low dose aspirin, the overall 
result was marginally protective. These two meta-analyses were subjected by us to 
cumulative meta-analysis and correlation studies. 
7.2.1. Cumulative meta-analysis. 
We conducted cumulative meta-analyses of the selected meta-analyses 
(without conducting new meta-analyses and adding new studies) to detect a 
possible time-dependent effect. The cumulative analysis route displays results 
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accumulated over time: that is, the second row presents a summary analysis 
comprising the first two studies; the third row presents a summary analysis 
comprising the first three studies, and so on through the final row. When the data 
are arranged by year of publication this shows the effect measure (relative risk) 
that could have been achieved at any point in time with each new study’s arrival; 
furthermore, the changes in the final conclusion can be examined over time. For 
the cumulative meta-analyses the Comprehensive Meta-Analysis Version 2.0 
(Biostat, Engelwood NJ) was used. Heterogeneity among studies was assessed 
using the Q statistic and the I-squared test. If the Q statistic (P value) is <0.05, it 
represents a high degree of variance among the studies analyzed, and the results 
are quantified by I-squared values. I-squared between 25%-50% signifies low 
heterogeneity, between 50%-75% moderate heterogeneity, and >75% signifies 
high heterogeneity [9]. Publication bias was analyzed using Funnel plots for 
detecting the presence of gray literature and assessing its impact on the analysis. 
The number of unpublished studies (K) that were possibly absent from our analysis 
was determined; if evidence of publication bias occurred (K>0), then adjusted 
point estimates (RR) were calculated based on the number of omitted studies (K) 
using the Duval and Tweedie’s trim-and-fill method.  
7.2.2. Correlation studies. 
We correlated the journal’s impact factor, citation number of each paper by 
using Google scholar during May 2015 and their sample size, with the RR of the 
study’s primary results. In the case of antioxidants, we also correlated the journal’s 
impact factor with the quality of the paper, by using the Cochrane Collaboration 
method [10]. This method demonstrates which articles satisfied all quality 
assessment criteria (no risk of bias) and which articles have not satisfied all quality 
assessment criteria. Comparison of continuous variables was conducted by the 
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Mann Whitney U test, and correlations between variables were calculated by the 
Spearman method.  
7.3. Results. 
The two meta-analyses included in this review were subjected to quality 
assessment, where the total AMSTAR scores were high (where both studies had 
maximum scores of 11). This suggests that the studies included in the meta-
analysis are not subjected to clinical and methodological heterogeneity that may 
affect the validity of the overall results. The conducted cumulative meta-analysis 
did not show statistically significant heterogeneity since all the P values of the Q 
tests were less than 0.05 and the I-square were less than 50%.    
7.3.1. Antioxidant studies.  
The first RCT included in the antioxidant meta-analysis was published in 
1994 and the most recent one was published in 2011. The sample sizes of the 15 
included studies ranged between 60-9969 subjects, the journals’ citation impact 
factor ranged between 0.60-54.42, and the number of citations of each paper 
between 13- 857 (between 2.17/year and 53.56/year) (Table 7.1). 
The median sample size of the positive trials (median 267) was tenfold 
smaller than the sample size of the negative trials (median 2120) (P=0.017). There 
was a significant positive correlation between study size and RR (rho=0.74; P 
=0.0016). There was no significant correlation between RR and citation number 
(rho=0.239), or between RR and the journal’s impact factor (rho=0.332). In 
contrast, the journal’s impact factor significantly correlated with the number of 
citations per year (rho=0.82; P =0.00016). Overall, the impact factor of the journal 
did not correlate with the quality of the papers as measured by Biberio- Salle et al 
[5] by using the Cochrane Collaboration method. Three studies that fulfilled all 
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quality criteria (25, 26, 30), with no risk of bias, had a RR of more than 0.9 (0.97, 
1.20 and 1.03), showing no protective effect of antioxidant on pre-eclampsia. 
During the first 12 years, in 5 studies, the cumulative meta-analysis revealed 
that there was a seeming significant protective effect of antioxidant vs. placebo on 
the rates of preeclampsia. This effect gradually diminished and was nullified by 
larger studies by 2006 (Figure 7.1). After the analysis of the publication bias using 
the funnel plot, the analysis detected five missing studies (Figure 7.5) and after 
incorporating the studies in the analysis the overall results shows more non 
protective effect of the antioxidant (RR=0.91 in the original meta-analysis, vs. 
RR= 1.01 adjusted meta-analysis) (Table 7.3). 
7.3.2. Low dose aspirin studies.  
The first RCT included in the low dose aspirin meta-analysis was published 
in 1986 and the most recent one was published in 2012. The sample sizes of the 14 
included studies ranged between 44 and 8257 subjects, the journals’ citation 
impact factor ranged between 1.41 -54.42, and the number of citations of each 
paper  was between 9-482 (0.43/year-16.62/year) (Table 7.2). 
The median sample size of the positive trials measuring IUGR (median 72) 
was 15 fold smaller than the sample size of the negative trials (median 3019) 
(P=0.006). Similar trends were seen for preterm delivery and rates of preeclampsia 
(Table7.2). There was a trend toward significant positive correlation between study 
size and RR for IUGR (rho=; P =0.06). There was no correlation between RR and 
citation number, or between RR and the journal’s impact factor. In contrast, the 
journal’s impact factor significantly correlated with the number of citations per 
year (rho=0.55; P =0.05).  
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The cumulative meta-analysis revealed that during the first 8-11 years, there 
was a significant protective effect of low dose aspirin vs. placebo on the rates of 
IUGR, prematurity and preeclampsia. This effect gradually diminished and was 
either nullified or remained marginally significant which was caused by larger 
studies starting in 2006 (Figures7.2- 7.4). After the analysis of the publication bias 
using the funnel plot, the analysis detected five to six missing studies and after 
incorporating the studies in the three meta-analyses the overall results showed 
marginally more significance. (from RR=0.77 in the original preeclampsia meta-
analysis to RR= 0.83 in the adjusted meta-analysis; from RR=0.86 in the original 
preterm birth meta-analysis to RR= 0.98 in the adjusted meta-analysis; and from 
RR=0.80 in the original IUGR meta-analysis to RR=1.93 in the adjusted meta-
analysis) (Table 7.3). 
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Table 7.1. Details of the RCTs included in the meta-analysis of antioxidants 
for preventing preeclampsia. 
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Study Name 
 
 
Year 
Sample 
size RR Journal name (impact factor) 
Number of 
citation 
Citation 
 per year 
Han [20] 1994 100 0.10 Chinese Med J (2.34) 46 2.19 
Chappell [21]  1999 283 0.46 Lancet (39.20) 857 53.56 
Sharma [22] 2003 100 0.48 Int J Gynecol Obstet (1.56) 68 5.67 
Steyn [23] 2003 200 1.00 J Obstet Gynaecol (0.60) 53 4.42 
Beazley [24] 2005 251 0.92 Am J Obstet Gynecol (3.97) 137 13.70 
Poston [25] 2006 1877 0.97 Lancet (39.20) 57 6.33 
Rumbold [26] 2006 2395 1.20 NEJM (54.42) 398 44.22 
Rumiris [27] 2006 60 0.24 Hypertens  Preg (1.19) 80 8.89 
Spinnato [28] 2007 159 0.88 Obstet Gynecol  (4.80) 105 13.13 
Banerjee [29] 2009 1355 0.99 J Obstet Gynecol Res (0.90) 13 2.17 
Villar [30] 2009 707 1.03 BJOG (1.56) 113 18.83 
McCance [31] 2010 2363 0.81 Lancet (39.20) 55 11.00 
Roberts [32] 2010 749 1.07 NEJM (54.40) 201 40.20 
Xu [33] 2010 9969 1.04 Am J Obstet Gynecol (3.97) 89 17.80 
Vadillo [34] 2011 444 0.75 BMJ (16.30) 80 20.00 
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Table 7.2. Details of the RCTs included in the meta-analysis of low dose 
aspirin for preeclampsia. 
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Study name Year 
RR (sample size) 
Journal name 
(impact factor) 
Number 
of 
citations 
 
Citation 
per year Preeclampsia Preterm birth IUGR 
Wallenburg [35] 1986 0.07 (44) 0.12 (44) 0.73 (44) Lancet (39.21) 482 16.62 
Benigni [36] 1989 - 0.38 (33) 0.31 (33) NEJM (54.42) 249 9.58 
Schiff [37] 1989 0.13 (65) 0.31 (66) 0.30 (65) NEJM (54.42) 314 12.08 
McParland [38] 1990 0.11 (100) - 1.08 (100) Lancet (39.21) 160 6.40 
Vinnika [39] 1993 0.84 (197) - 0.46 (197) BJOG  (3.86) 61 2.77 
Caspi [40] 1994 0.19 (47) 0.75 (47) 0.52 (94) 
Am J Reprod 
Immunol  
(2.67) 
9 0.43 
CLASP [41] 1994 0.88 (7974) 0.90 (7974) 0.90 (8257) Lancet (39.21) 72 3.43 
Hermida [42] 1997 0.43 (100) 0.20 (100) 0.50 (100) Hypertension (7.63) 49 2.72 
Gallery [43] 1997 - 0.65(108) - 
Hypertension 
Pregnancy 
(1.41) 
20 1.11 
MFMU [44] 1998 0.90 (2503) 0.93 (2503) 1.19 (2503) NEJM (54.42) 467 27.47 
Grab [45] 2000 1.43 (43) - - 
  Ultrasound  
Obstet Gynnecol 
 (3.85) 
26 1.73 
Vainio [46] 2002 0.20 (86) - 0.33 (86) BJOG  (3.86) 151 11.62 
Yu [47] 2003 0.95(554) 0.90 (554) 0.90 (554) 
  Ultrasound  
Obstet Gynnecol 
(3.85) 
100 8.33 
Villa [48] 2012 0.72(121) - 0.33 (121) BJOG  (3.86) 49 16.33 
Ayala [49] 2012 0.94(350) 0.38 (350) 0.49 (350) Chronobiol Int (2.88) 26 8.67 
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Table 7.3. Duval and Tweedie's Trim and Fill summary data for analysis of 
publication bias in the two meta-analyses. 
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  Random Effects Model   
  
Studies 
Trimmed 
Point 
Esti-
mate 
Lower 
Limit 
Upper 
Limit Q-Value 
Anti-Oxidant  
& 
Preeclampsia 
Observed Values   0.91 0.80 1.03 23.55 
Adjusted Values 5 1.01 0.94 1.16 46.05 
Low Dose 
Aspirin & 
Preeclampsia 
Observed Values   0.77 0.62 0.95 19.95 
Adjusted Values 5 0.83 0·64 1.07 35.61 
Low Dose 
Aspirin & 
Preterm Birth 
Observed Values   0.86 0.76 0.98 13.37 
Adjusted Values 5 0·89 0.76 1.05 25.76 
Low Dose 
Aspirin & 
IUGR 
Observed Values   0.80 0.65 0.99 19.00 
Adjusted Values 6 1.93 0.74 1.18 33.97 
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Figure 7.1. Cumulative chronological meta-analysis of risk ratio in RCTs 
investigating the effectiveness of antioxidants for preeclampsia. 
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Figure 7.2. Cumulative chronological meta-analysis of preeclampsia of RCTs 
of women at risk of preeclampsia who took either aspirin or placebo. 
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Figure 7.3. Cumulative chronological meta-analysis of preterm birth of RCTs 
of women at risk of preeclampsia who took either aspirin or placebo. 
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Figure 7.4. Cumulative chronological meta-analysis of IUGR sorted by the 
year of publication for trials of women at risk of preeclampsia who took either 
aspirin or placebo. 
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Figure 7.5. Publication bias using funnel plot of preeclampsia prevention by 
antioxidant meta-analysis (open circles are the original studies and closed 
circles are the added studies during adjustment). 
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7.4. Discussion. 
Studies published in high impact factor journals are cited significantly more. 
Naturally, this leads physicians to encounter them more often and possibly assume 
that these studies reflect the right clinical answer. Similar to our findings, a recent 
study has shown that the impact factor predicts 59% of the variation in citations of 
systematic reviews. However, the distribution of citations was obviously skewed 
[11]. Importantly, our study shows that high impact factor journals do not exhibit 
higher likelihood of predicting a correct answer, which implies that the higher 
citation impact does not translate into more correct clinical impact. The fact that 
they are cited substantially more may thus create a reporting bias. For example, the 
second published study by Chappel et al. on antioxidants [21] showed a 54 percent 
reduction in risk of preeclampsia with antioxidants and exhibited the highest 
number of citations to date (n=857), which may impact clinicians’ decision in 
considering patient care. Yet, this study did not predict correctly the overall effect 
of antioxidants, which is null.  
What are the reasons that first studies often declare a dramatic effect only to 
be nullified later?  Our study offers several plausible explanations: 
Firstly, as shown by our results, studies with smaller sample sizes are more 
likely to be biased against the null hypothesis and suggest positive results. Small 
studies are easier to execute and bring to completion, so naturally they are more 
likely to be published first. As major journals are seeking novel discoveries, they 
may be more inclined to accept such papers, and hence, to be exposed to the risk of 
bias against the null hypothesis. 
Secondly, there is a serious and systematic bias against the null hypothesis in 
the publication process [12, 13]. We and others have shown that negative studies 
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(i.e. those not showing a significant effect) are less likely to be submitted by their 
authors [14], less likely to be accepted for scientific presentations or publication by 
journals [13, 15], less likely to be quoted by the lay media, [16] and less likely to 
be cited in the peer review literature [17]. When these effects are combined, a 
serious bias can be produced, potentially creating a spurious positive effect. As 
years go by, larger studies are published, and the slow-to-be-accepted negative 
papers manage to find their way to PubMed –Medline [18], hence the original 
spurious positive effect may be diluted and finally nullified. This is further shown 
by the assessment of publication bias, suggesting that there are five to six studies 
that have not been published and after incorporating the missing studies the 
adjusted overall effect shows further nullification of the signal.   
With respect to Impact Factor, it has been and continues to be the leading 
journal quality indicator despite recognized weaknesses such as the effects of self-
citation, review articles, the total number of articles published, and English 
language bias [3]. Related to the issues addressed in the present study, a recent 
evaluation of 13 trauma journals concluded that the impact factor of a journal was 
a poor measure of the clinical relevance of its papers. Specifically, the authors 
found that high impact journals did not address clinical research in surgery and 
when they did, there was a delay before such papers were cited [18]. 
In the case of preeclampsia, the biological plausibility of either antioxidants 
or low dose aspirin in experimental models has led to great therapeutic hopes, 
which can probably explain the enthusiasm that accompanied the first positive 
studies. With both antioxidants and low dose aspirin, the cumulative chronological 
meta-analyses revealed that during the first years, there was a seeming significant 
protective effect on the rates of preeclampsia and its complications. With both 
modalities, the suggested protective effects gradually disappeared and were either 
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nullified or remained marginally significant by larger, later studies. Our study 
highlights the importance of the cumulative meta-analysis as a powerful evaluation 
tool, which has been used more and more often to decide when additional RCTs 
are no longer needed therefore suggesting an effect has been proven beyond 
reasonable doubt [19].   
The fact that initial papers in high impact journals did not predict better the 
clinical utility of antioxidants or low dose aspirin for preeclampsia is consistent 
with the finding that there were no consistent differences in quality between high 
impact journals vs. papers in less prestigious journals. This highlights one of the 
criticisms against the citation impact factor, as it may be informative about the 
overall quality of the journal, but not of specific papers [11]. 
7.5. Conclusion. 
In conclusion, initial studies, often published in high citation impact factor 
journals, are cited significantly more times, but do not exhibit higher likelihood of 
predicting a correct answer. Studies with smaller sample sizes are more likely to be 
biased against the null hypothesis and as such, cumulative meta-analysis is an 
effective tool to predict potential bias against the null hypothesis. 
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Chapter 8: General discussion.  
8.1. Discussion of research findings.  
 Although nonrandomized observational studies are of lower quality than 
randomized studies, nonrandomized studies have some advantages, as they are 
conducted over a long period of time with the number of participants increasing 
cumulatively [1]. The almost total lack of randomized control studies of drug 
therapy during pregnancy makes observational studies the main source of evidence 
in teratology, where data can be synthesized from multiple large prescription 
databases. This has led to a more recent form of cohort publications based on large 
numbers of patients and exposures, albeit retrospective in nature. These studies’ 
strengths lie in their large size, but the problem is that the larger cohort studies will 
take many years to accumulate and the rate of association of new drugs used by 
pregnant women and abnormalities will still need to be estimated in the meantime. 
In contrast, small cohort studies conducted by different countries and research 
centers will be published years before the large cohort studies can finish collecting 
their data. The meta-analysis of small nonrandomized cohort studies from different 
sources, but with the same teratogenic questions, can give us early estimates about 
drug use during pregnancy, and one can reassure pregnant women who have taken 
the drug before they knew they are pregnant or pregnant women who need to use a 
certain drug are acting on reliable information.  
 The current thesis shows, with sufficient evidence how similar are the 
conclusions based on the meta-analysis of small studies and those from very large 
cohort studies in estimating teratogenicity [2]. This is obvious, especially with 
untreated epilepsy, proton pump inhibitors and H2 blockers being safe, while 
valproic acid may cause malformations.  
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This study enables researchers, clinicians, drug companies and regulators to 
trust the meta-analyses of small underpowered controlled studies in identifying the 
signals of new drugs used during pregnancy earlier in the course of marketing.  
Retrospective registries can be useful as we estimate, based on the available 
data, that there is a 4.5 fold amplification factor in retrospective reports compared 
to prospective studies of the same compounds by the same company for risk of 
congenital malformations from drug exposure during pregnancy [3]. If the 
retrospective registries lead to stable increases in teratogenic signal, this must also 
mean that, if the retrospective cohort does not show malformation rates above the 
expected baseline of 3-5%, the drug is probably not associated with increased 
teratogenic risk. 
Meta-analysis of observational studies is an effective tool to answer 
unresolved research questions in teratology. Meta-analysis has an advantage that 
gives more statistical power as similar results from different studies on the same 
research question are combined. Meta-analysis also allows a more truthful 
representation of different populations than is delivered by the specific study 
estimators.  
The use of meta-analysis can generate new hypotheses and insight on drug 
safety during pregnancy, such as the case of H1 antihistamine in treatment of NVP. 
18 of our 33 cohort studies looked specifically at H1 antihistamine use for the 
treatment of NVP and were included in our analysis. The results showed no 
association between H1 antihistamine use as an antiemetic and major 
malformations, which is consistent with previous studies. Yet, with an odds ratio 
(0.95) and lower limit of the confidence interval (0.87) less than one, our results 
also may suggest a trend towards a protective effect of antihistamines [4].   
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However, several studies have shown that NVP itself has a protective effect 
on the unborn baby, with mothers who experience morning sickness having better 
birth outcomes including reduced risks of spontaneous abortion, preterm birth, 
birth defects, and children with higher IQ [5]. There are two well-accepted theories 
of how NVP may play a role in better pregnancy outcomes. The first is that the 
presence of NVP in pregnancy may prevent the ingestion of harmful teratogens, 
either through lack of appetite or physical sickness, therefore protecting the unborn 
fetus [6]. The second theory suggests that NVP is secondary to high hormone 
levels associated with viable pregnancies, and therefore the symptoms themselves 
are not protective, merely they are a negative side effect. Based on the latter theory 
rather than being protective, NVP could then be an indication of a more optimal 
pregnancy, which would result in better outcomes [7]. However one particular 
negative effect of NVP can be the inability to obtain adequate nutrition as a result 
of emesis or lack of desire to eat. Women who are treated for their NVP will not 
suffer the consequences of inadequate nutrition. It is therefore reasonable to 
assume that those women who suffer from NVP (i.e. have optimal hormone levels 
for the best outcomes) and are able to obtain optimal nutrition (because they used 
antiemetic treatment), which could explain the protective effects of antihistamines 
both reported by us and other studies. However, more research studies, with 
carefully planned control groups, are required in order to definitively answer 
questions surrounding these possible protective effects previously observed. 
This study provides important information to both pregnant women and their 
health care providers regarding the safety and risk of H1 antihistamines use during 
this sensitive time. Although our conclusions are based on a large number of 
studies, many others exist which also address fetal safety after exposure to H1 
antihistamines. These particular studies suffer from methodological issues that 
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made data extraction for meta-analysis difficult and/or impossible. Much of this is 
the result of issues presented when studying the safety of medication in pregnancy. 
However, more observational controlled studies, with more consistent 
methodology are necessary in order to best assess the safety and risks associated 
with not only H1-AH use in pregnancy, but all medication in general. 
Cumulative meta-analysis in drug therapy is an essential tool used in 
predicting when the direction of the conclusion starts to change, from effective to 
no effect may even cross to negative effect, after introducing more trials. The 
problem is that the primary studies that discover the new remedy usually suffer 
from limited sample size. These studies are often published in high impact factor 
journals and are highly cited causing the medical community to trust their 
preliminary results. The cumulative meta-analysis of RCTs published on the 
protective effects of antioxidants and low dose aspirin against preeclampsia clearly 
shows the potential bias against the null hypothesis [8]. This study should 
encourage researchers who perform new trials on drug therapy to conduct 
cumulative meta-analysis of all previous trials to give the medical community 
more insight of the direction of the overall results.  
8.2. Methodological challenges in observational studies included in meta-
analyses.   
Although many observational control studies so far have addressed fetal 
safety after exposure to specific chemicals, they suffer from methodological issues 
including lack of important information such that performing meta-analyses is 
challenging. Therefore, there is a need for clear guidelines for researchers who 
perform observational studies to help other researchers in including them in meta-
analyses to increase the sample size and reduce clinical heterogeneity that is often 
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present in the exposed groups, control groups (comparison group) and in 
pregnancy outcomes measures. 
8.2.1. Limitations in the exposed group. 
The limitations in the exposed group are that the gestational age and 
duration, daily dose and the drug indication are not defined or reported 
consistently. In addition, the exposed group should optimally be free of conditions 
that are known to cause adverse pregnancy outcomes, except for the disease that is 
being treated by the drug under study; however, many studies fail to practice 
and/or report such exclusion.   
8.2.2. Limitations in the control group. 
The comparison (or control) group must be composed of healthy volunteers 
who have not been exposed to the specific drug under study and/or the same 
pharmacological class of the drug under study. Ideally they must not have been 
exposed to chemicals that may cause unwanted fetal effects. In addition, the 
control group must be free of any disease that may affect pregnancy outcome. The 
control group and the exposed group should optimally be matched for maternal age 
and, if possible, for other confounders such as nicotine and alcohol consumption, 
diabetes, gravidity, parity, previous abortions and/or malformations in previous 
pregnancies.   
The above conditions are not followed and/or reported by some studies. In 
some studies, a disease matched control group is needed because the control group 
has the same disease as the exposed group but does not take medications, the 
control group is treated for the condition with another class of drugs, or the control 
group takes the medication under study but not during the first trimester of 
pregnancy.  
146 
 
8.2.3. Limitations in the pregnancy outcomes. 
Regarding malformation, birth defects should be classified as major or minor 
and the pediatrician who follows up on a case should confirm the severity of the 
malformation. When reporting the major malformation, it is important that 
researchers not just give the number of each kind of malformation because 
sometimes one case has more than one kind of malformation and this may cause a 
multiple counting of malformations; instead, researchers should also indicate the 
number of exposed subjects and how many experienced major malformations. 
Because some research studies did not follow these guidelines, this caused 
exclusion of the studies from our meta-analysis.  
Most of the studies examined the association between prenatal exposure to 
drugs and major birth defects and they did not study other adverse pregnancy 
outcomes, such as spontaneous abortions, prematurity, stillbirth, infant death, 
perinatal death, therapeutic abortions, elective abortion, low birth weight, abnormal 
head-circumference and abnormal Apgar score. These outcomes are equally 
important to address teratogenic potential. 
The reasons behind in utero death may be due to birth defects or due to other 
causes reasons; however, these incidents are inconsistently reported. Information 
on abortions should clarify if they were spontaneous, therapeutic or elective. 
8.2.4. Limitations in general. 
All the important raw data, such as pregnancy numbers, live births, the 
gestational ages at birth, the number of premature births, rates of spontaneous 
abortions and all deaths; should be reported, but some studies did not report all 
necessary information. Moreover, often updated studies included old data 
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published in the past without referencing it, and this could have caused double 
counting or an overlap when performing meta-analysis.  
It is evident that in case control studies the cases and controls are selected 
based on the presence of congenital anomalies. Sometimes we are missing 
important data necessary to conduct meta-analysis. 
Case control Studies are retrospective and observational. We first identify 
the group that has the health outcome of interest (malformations, which in case 
control study are cases). Then we identify a group that did not have the health 
outcome of interest (malformations), which in case control study are controls. Then 
we determine whether or not the participants from each group had a particular 
exposure to H1 antihistamine in the past. Table 8 provides the information needed 
to conduct the meta-analysis for the cohort study. 
In the case control group, the following information is provided:  
1- Number of cases (as defined by the case control study that has the 
outcome) which are equal to A+C.   
2- Number of controls (as defined by case control study that has no 
outcome) which are equal to B+D.  
Some case control studies did not provide all the necessary information 
needed, such as A or C and B or D. This caused an exclusion of these studies from 
meta-analysis that may provide important evidence of the fetal safety/risk of the 
drug under study. 
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Table 8. Information needed to conduct the meta-analysis for cohort study. 
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 Malformation cases Total number 
Exposed group A A+B 
Control group  C C+D 
A: Malformation cases that are exposed to the drug under study. 
B: Normal cases that are exposed to the drug under study. 
C: Malformation cases that are not exposed to the drug under study. 
D: Normal cases that are not exposed to the drug under study. 
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8.2.5 Limitations due to study bias. 
Study bias is an error that leads to false positive or negative estimation of the 
risk. Bias can have different sources from study design to the process of 
publication [9]. There is always a challenge to decrease the sources of bias and 
increase the generalizability of the data. But, due to the limited data on drug fetal 
safety in the literature and lack of RCTs, observational studies have to be included 
in meta-analyses even though they did not always control for potential bias. This is 
one of the big limitations of meta-analyses conducted in this field.  
Bias by indication is one of these limitations, where the disease itself that is 
intended to be treated by the drug under study, may cause or protect from the 
unwanted pregnancy outcome. This bias can be overcome by proper study design 
by having a disease- matched control and if one has large pool of studies, one can 
conduct a sensitivity analysis that includes only observational studies where 
confounders were adequately addressed in the study design and analysis.  
Maternal fetal research deals with observational studies where the 
population is usually pregnant women who voluntarily chose to use the drug under 
study or accidently took the drug before they knew that they were pregnant. The 
population under study may include women with health insurance, good education 
and/or previous unwanted pregnancy outcome, who will seek help from the 
medical community regarding drug safety during pregnancy [10]. A selection bias 
may then be generated and the data may not be easily generalized. This limitation 
must be acknowledged in the original studies by reporting the demographic 
characteristics of the included population and proper matching for variables such 
as previous adverse pregnancy outcome between the exposed and the control 
groups. 
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There is always a chance that the meta-analysis missed some studies because 
of publication bias, where studies with significant results are more likely to be 
published in the literature than studies with results that are not statistically 
significant. Generating a funnel plot is a common way to address publication bias 
but if the number of included studies is less than ten then this method cannot be 
used due to lack of sensitivity [11]. Missing studies are not always due to 
publication bias. There are other sources that may lead to missing studies such as 
language bias where non-English studies are more likely to be missed, citation bias 
where studies with non-significant results are less cited by other papers and more 
likely to be missed, and availability bias where studies with keywords that did not 
match the search terms are more likely to be missed [12].  
These limitations cannot be avoided most of the time since the original data 
were collected by different groups of researchers with different criteria. Generating 
widely acceptable guidelines for observational studies on specific topics on fetal 
drug safety can help limit possible biases and may help achieve more precise 
estimates of risk/safety of fetal drug exposure during pregnancy.   
8.3. Conclusion. 
The following points are the general conclusions of the included studies in 
this thesis: 
1- Meta-analysis of smaller studies appears to generate correct signal in 
estimating human teratogenicity years before large and methodologically superior 
cohort studies are published [2]. 
2- The present study confirms a major and consistent bias against the null 
hypothesis in retrospective registry studies which needs to be considered when 
interpreting such data. Spontaneous reporting is highly selective toward adverse 
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events, as families with normal pregnancy outcomes are less likely to report them 
[3].   
3- Overall, cetirizine is not associated with a clinically important increase in 
risk of major malformations or other adverse fetal outcomes. Confounding of 
results due to use of the drug for asthma must be considered [13]. 
4- Based on our meta-analyses, which include a large number of studies, H1 
antihistamines are not associated with an increased risk of major malformation or 
other adverse fetal outcomes. This study provides important information to both 
pregnant women and their health care providers regarding the safety and risk of H1 
antihistamine use during this sensitive time [4]. 
5- Initial intervention studies, often published in high impact factor journals, 
are cited significantly more times but do not exhibit a higher likelihood of 
predicting a correct long term answer. As such, cumulative meta-analysis is an 
effective tool in predicting potential bias against the null hypothesis and the need 
for additional studies [8]. 
8.4. Area of future research.  
In the area of therapeutics in pregnancy, we need to continue to study the 
safety and efficacy of drugs specific to this population. Conducting small cohort 
studies in different parts of the world and combining them in meta-analyses is an 
effective tool for this purpose. Furthermore, conducting cumulative meta-analyses 
is important whenever new studies emerge in an effort to continue to examine the 
safety and efficacy of therapies in pregnancy, or deciding that sufficient data 
already exists. 
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Appendix 2: Detailed characteristics of the included examples for Chapter 3. 
1) Benzodiazepines and risk of major malformations: 
In 1998 a meta-analysis of benzodiazepine and major congenital 
malformation concluded that benzodiazepine were not associated with risk of 
major malformation (odds ratio 0.90; 95% confidence interval 0.61 to 1.35). This 
meta-analysis combined 7 small cohort studies (n ˂ 335 in each study). The last 
published study was in 1997 [1].  
In 2007 a Swedish group published a large cohort study from Swedish 
Medical Birth Register. The total number of group exposed to benzodiazepine was 
1929. The final conclusion was the same as the meta-analysis (odds ratio 1.12; 
95% confidence interval 0.91 to 1.36) [2]. An updated meta-analysis published in 
2011 combined the old meta-analysis with two other cohort studies including the 
large one and the final conclusion did not change (odds ratio 1.07; 95% confidence 
interval 0.91 to 1.25) [3]. 
2) Untreated epilepsy and major malformations: 
In 2004 a meta-analysis of the association between untreated epilepsy and 
major malformation was published. The conclusion was that the risk for congenital 
malformation in the offspring of women with epilepsy who had not used 
antiepileptic was not higher than among nonepileptic controls (odds ratio 1.92; 
95% confidence interval 0.92 to 4.00). This meta-analysis combined 10 small 
cohort studies (n ˂ 99 in each study). The last published study was in 2001 [4]. 
In 2009 a group from Norway published a large cohort study from The 
Medical Birth Register of Norway. The total number of children of women with 
untreated epilepsy was 1900. The final conclusion was similar to that of meta-
analysis (odds ratio 1.0; 95% confidence interval 0.8 to 1.4) [5].  
3) Proton Pump Inhibitors and major malformation: 
In 2002 a meta-analysis of proton pump Inhibitors and major malformation 
was published with the final conclusion that proton pump Inhibitors are not 
associated with increased risk of major malformation (Relative Risk 1.18; 95% 
confidence interval 0.72 to 1.94). This meta-analysis combined 5 small cohort 
studies (n˂ 276 in each study). The last published study was in 2001 [6]. An 
updated meta-analysis published in 2009 combined the old meta-analysis with two 
more recent cohort studies (one study in 2005 and the other one in 2008), the new 
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meta-analysis gave the same final conclusion (odds ratio 1.12; 95% confidence 
interval 0.86 to 1.45) [7]. 
In 2010 a group from Denmark published a large cohort study using data 
from The Medical Birth Register, the Prescription Drug Register, the National 
Patient Register, the Center Person Register, and Statistics Denmark. The total 
number in the group exposed to proton pump Inhibitors was 3651. The final 
conclusion was comparable to the meta-analysis (odds ratio 1.10; 95% confidence 
interval 0.91 to 1.34) [8].  
4) Histamine 2 (H2) blocker and major malformations:  
In 2009 a meta-analysis of H2 blocker and major malformation was 
published [9]. This meta-analysis combined four cohort studies, three of them 
small, and the fourth, which was the most recent one consisted of a large cohort 
study that at that time was published as an abstract in 2008 [10] and the full study 
published in 2010 [11]. The big study was removed from the meta-analysis by us 
and the remaining three small cohort studies were recombined using 
comprehensive meta-analysis version 2 software. The meta-analysis, after 
removing the large cohort study showed no association with the malformation 
(odds ratio 1.00; 95% confidence interval 0.60 to 1.65) and the most recent study 
in the reconstructed meta-analysis was in 2005 (Figure 3).  
In 2010 a group from Israel published a large cohort study; using data from 
Clalit Health Services in Israel, [11]. The total number of exposed group to H2 
blocker was 1148. The final conclusion was the same as the reconstructed meta-
analysis (odds ratio 1.14; 95% confidence interval 0.89 to 1.45).  
  
162 
 
 
 
 
 
 
 
 
 
Figure 3. Forest plot of the incidence of congenital malformations after in 
utero exposure to H2 blockers (without the large cohort study). 
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 Study name (year) Statistics for each study Events / Total Odds ratio and 95% CI
Odds Lower Upper Relative Relative 
ratio limit limit p-Value Exposed Control weight weight
Magee (1996) 0.60 0.14 2.54 0.48 3 / 142 5 / 143 10.63
Ruigomez (1999) 1.37 0.88 2.13 0.16 31 / 555 64 / 1547 52.26
Garbis (2005) 0.74 0.39 1.38 0.34 13 / 553 44 / 1390 37.12
1.00 0.60 1.65 0.99
0.01 0.1 1 10 100
Favours exposure Favours control
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5) Angiotensin converting enzyme inhibitors (ACEI) and major 
malformations: 
In August 2011 a meta-analysis of ACEI and major malformation was 
published, concluding that ACEI exposure was not associated with major 
malformation compared to “other” antihypertensive exposed controls (odds ratio 
1.41; 95% confidence interval 0.66 to 3.04). This meta-analysis combined 4 small 
cohort studies (n ˂ 210 in each study). The last published study was in 2011. 
Moreover, there were another two meta-analyses in the same publication, one 
examining the association between the ACEI exposed group versus healthy 
controls (5 studies) and the other looked for the association between “other” 
antihypertensive exposed group versus healthy control (4 studies). The two meta-
analyses showed an association between congenital malformation and the use of 
ACEI (odds ratio 1.78; 95% confidence interval 1.07 to 2.94), or the use of “other” 
antihypertensive (odds ratio 1.45; 95% confidence interval 1.15 to 1.83) was 
significant [12].   
In September 2011 an American group published a large cohort study from 
the California birth certificate data and the Kaiser Permanente Northern California 
(RER). The total number of exposed group to ACEI was 704 (more than the total 
number of the combined studies in the meta-analysis). The association between 
exposure to ACEI and “other” antihypertensive was calculated by us. This was 
done by creating 2x2 table and by using the risk in the ACEI exposed group 
(58/704) and the risk of “other” antihypertensive exposed as a control (327/4390). 
The odd ratio was calculated (odds ratio 1.12; 95% confidence interval 0.83 to 
1.49) and the conclusion was ACEI exposed group was not associated with major 
malformation compared to “other” antihypertensive exposed controls and this 
concurred with the meta-analysis conclusion. Additionally, the large cohort study 
measured a positive association between ACEI exposed group versus healthy 
control (odds ratio 1.58; 95% confidence interval 1.21 to 2.06) and between 
“other” antihypertensive exposed group versus healthy control (odds ratio 1.41; 
95% confidence interval 1.26 to 1.58). In conclusion, this large study agreed with 
the meta-analysis of small studies that ACEI and “other” antihypertensive had the 
same risk estimate [13].    
6) Valproic acid and major malformations: 
In 2006 a meta-analysis of valproic acid and major congenital malformations 
was published, concluding that valproic acid was associated with risk of major 
malformation (Relative risk 3.77; 95% confidence interval 2.18 to 6.52). This 
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meta-analysis combined 3 small cohort studies (n ˂ 159 in each study). The last 
published study was in 1999 [14]. 
In 2010 the EUROCAT antiepileptic group published a large observational 
study. The total number of babies exposed to valproic acid was 180. The 
conclusion was similar to that of the meta-analysis, where the use of valproic acid 
monotherapy was associated with significantly increased risks for 6 of the 14 
malformations under consideration example: spina bifida relative risk = 12.7, 95% 
CI (7.7-20.7) [15]. 
7) Valproic acid and intellectual development:  
In 2010 a meta-analysis of valproic acid exposure in pregnancy and 
intellectual development was published, showing that valproic acid was associated 
with reduced intelligence (full-scale IQ was significantly lower (P = 0.001) in the 
valproic acid group when compared to the control group). This meta-analysis 
combined 3 small cohort studies (n ˂ 42 in each study). The last published study 
was in 2005 [16]. 
In 2010 a group published a prospective observational study by using data 
from 25 epilepsy centers in the United State and the United Kingdom. The total 
number of exposed group to valproic acid was 92 (more than the total number of 
the combined studies in the meta-analysis). The results showed that children 
exposed to valproic acid had an IQ score 9 points lower than the score of those 
exposed to lamotrigine (P= 0.009). In this study, the lamotrigine exposed group 
was considered as a control group because in this study there was no control group 
of unexposed children included. The final conclusion indicates that valproic acid 
was associated with reduced intelligence [17]. 
8) Carbamazepine and intellectual development:  
In 2010 a meta-analysis of carbamazepine and intellectual development was 
published, concluding that carbamazepine was not associated with reduced overall 
intelligence (full-scale IQ was not significantly lower (P= 0.39) in the 
carbamazepine group compared with the control group). This meta-analysis 
combined 3 small cohort studies (n ˂ 87 in each study). The last published study 
was in 2005 [16]. 
In 2010 a group from the US and UK published a prospective observational 
study by using data from 25 epilepsy center in the United State and the United 
Kingdom. The total number of the exposed group to carbamazepine was 98 (more 
than the biggest study in the meta-analysis). The final conclusion was that children 
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exposed to carbamazepine had an IQ score 3 points lower than the score of those 
exposed to lamotrigine (P= 0. 0.20), where the P value was calculated by us from 
the existing data. In this model the lamotrigine-exposed group was considered as a 
control group because in this study there was no control groups of unexposed 
children included. The final conclusion agreed with the meta-analysis, that 
carbamazepine was not associated with reduced intelligence [17]. 
9) Maternal varicella-zoster infection and major malformations: 
  In March 1994 a meta-analysis of fetal risk of congenital varicella 
syndrome (CVS) after maternal varicella –zoster virus infection in pregnancy, 
combined 5 small observation studies (n < than 50 in each study). They found the 
weighted average risk for CVS associated with maternal varicella infection was 2.2 
% (95% confidence interval, 0 to 4.6 %; range, 0 to 9.1 %). The last published 
study included in was in 1994 [18].  
In June 1994 a joint large prospective study in Germany and United 
Kingdom was published. Between 1980 and 1993, 1739 pregnant women who had 
varicella during the first 36 weeks of gestation were followed up. The calculated 
risk of congenital varicella syndrome during the first trimester was 2/472 (0.4%, 
95% confidence interval, 0.05 to 1.5 %). The denominator (472) was all pregnancy 
infected during 0-12 weeks and continuing past 20 weeks gestation, this number 
was more than the total number of the combined studies in the meta-analysis The 
conclusion from both meta-analysis study and large prospective study was similar, 
where the risk of embryopathy associated with maternal infection with varicella-
zoster virus after first trimester was < 5% [19]. 
Quality assessment:  
All the selected studies were subjected to methodological quality assessment 
using the AMASTR method for meta-analytical studies [20], and the MINORS 
tool for the large cohort studies [21]. The 'assessment of multiple systematic 
reviews' (AMSTAR) is a tool consisting of an 11 item questionnaire, and each item 
has four possible answers. There is no overall scoring system in this method. The 
AMSTAR quality assessment tool falls into three ranges, High (9-11), Medium (5-
8), and Low (0-4) [22]. MINORS is a validated methodological index to assess the 
quality of non-randomized, observational studies. Two points are given for each 
question if the article reports and provides an adequate answer; one point is given 
if the article reports on the issue but the answer is inadequate; and no points are 
given if the article does not report the answer. The global ideal score is out of 24 
for comparative studies with a higher score representing greater quality. 
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Appendix 3: Characterization of studies included in the analysis of Chapter 4. 
1) Quetiapine: 
Data were from the Seroquel pregnancy registry up to July 2010. In the 
prospective report, there were six live births with congenital anomaly. The report 
had 167 live births, 29 cases of elective termination, 19 cases of miscarriage, and 3 
cases of fetal death, all the cases without congenital anomaly. In the retrospective 
report, there were 18 live births with congenital anomaly and two cases of elective 
termination with congenital anomaly. In the report there were 168 live births, 26 
cases of elective termination, 33 cases of miscarriage, and six cases of fetal death, 
all the cases without congenital anomaly. 
2) Quadrivalent human papillomavirus vaccine: 
Data were from the Merck pregnancy registry covering the period from first 
approval (June 1, 2006) to May 31, 2009. In the prospective report, there were 23 
cases of infants/fetuses with major birth defects (21 live births, one fetal death and 
one elective abortion) and one miscarriage with a major malformation. The total 
number of live births was 974, the total number of fetal death was 10, the total 
number of elective abortions was 65 and the total number of miscarriages was 64. 
In the retrospective report, there were 11 cases of infants/fetuses with major birth 
defects (8 live births, two fetal deaths, and one elective abortion) and one 
miscarriage with major malformation. The total number of live births was 190, the 
total number of fetal deaths was six, the total number of elective abortions was 21, 
and the total number of miscarriages was 44. 
3) Montelukast sodium: 
Data were from the Merck pregnancy registry covering the period from first 
approval (February 20, 1998) to July31, 2009. In the prospective report, there were 
eight cases of infants/fetuses with major birth defects (7 live births, and one 
elective abortion). The total number of live births was 245, the total number of 
elective abortions was two, and the total number of miscarriages was three, with no 
reports of fetal death. In the retrospective report, there were nine cases of 
infants/fetuses with major birth defects (9 live births) and two miscarriages with 
major malformations. The total number of live births was 56, there were 10 
miscarriages, and there were no fetal deaths or elective abortions. 
4) Itraconazole: 
Data were from pregnancies reported to the international pharmacovigilance 
department of the manufacturer (Janssen Pharmaceuticals) [1]. In the prospective 
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report, there were five cases of infants/fetuses with major birth defects (5 live 
births). The total number of live births was 156, the total number of fetal deaths 
was three, the total number of elective abortions was 15, and the total number of 
miscarriages was 25. In the retrospective report, there were 17 cases of 
infants/fetuses with major birth defects (14 live births and three elective abortions). 
The total number of live births was 108, the total number of fetal deaths was one, 
the total number of elective abortions was 26, and the total number of miscarriages 
was 31. 
5) Fluoxetine: 
Data included fluoxetine-exposed pregnancies reported to Lilly and its 
affiliates before April 1996 [2]. There were 658 first-trimester fluoxetine-exposed 
pregnancies with outcome other than miscarriage identified prospectively from 
spontaneous reports. There were 23 cases of major malformations reported in the 
658 pregnancies. A total of 426 pregnancies were reported retrospectively, with 89 
cases of malformations associated with fluoxetine exposure in the first trimester. 
6) Acyclovir: 
Data were from a published article based on the acyclovir in pregnancy 
registry, managed by Wellcome Co., between June 1, 1984 and June 30, 1990 with 
reports only from the United States [3]. In the prospective report, the number of 
infants with congenital abnormalities was five and the number of infants without 
congenital abnormalities was 96. In the retrospective report there were seven 
infants with congenital abnormalities and 24 infants without congenital 
abnormalities. 
7) Statins: 
Data were from a published article with reports from Merck and Co. to 31 
December 2002 [4]. In the prospective cases, there were six children with 
malformations and the denominator was the total live births (154) and total fetal 
deaths.4 In the retrospective cases, there were 13 offspring with congenital 
abnormalities (8 live births, 4 elective abortions, and one miscarriage). The 
denominator was 91, which included the total number of pregnancy outcomes. 
8) Mefloquine: 
Data were from a published article using the Hoffmann–La Roche global 
drug safety database for the time frame 31 January 1986 to 26 October 2010 [5]; 
only cases with first trimester exposure were included. Among prospective cases 
there were 38 infants and fetuses with birth defects. The denominator was 717, 
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which included all cases with birth defects (n = 38), normal infants (n = 635), 
normal fetuses (n = 4), and other disorders (not birth defects) (n = 40). Among the 
retrospective cases the number of infants/fetuses with birth defects after first 
trimester mefloquine exposure was 29. The denominator was 115, which included 
all birth defect cases (n = 29), normal infants (n = 70), normal fetuses (n = 4) and 
other disorders (not birth defects) (n = 12). 
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Appendix 5: Search strategies for Chapter 6. 
Set History 
1 H1 Antagonists, Histamine OR Antagonists, Histamine H1 Receptor OR Antihistaminics, 
H1 OR H1 Antihistaminics OR Receptor Blockaders, H1 OR H1 Receptor Blockaders OR 
Histamine H1 Blockers OR Histamine H1 Receptor Antagonists OR Histamine H1 Receptor 
Blockaders OR Antagonists, Histamine H1 OR Blockaders, Histamine H1 Receptor OR 
Antihistamines, Classical OR Classical Antihistamines OR Antihistaminics, Classical OR 
Classical Antihistaminics OR First Generation H1 Antagonists OR Antihistamines, Sedating 
OR Sedating Antihistamines OR Histamine H1 Antagonists, Non Sedating OR Second 
Generation H1 Antagonists OR H1 Antihistamines, Non-Sedating OR H1 Antihistamines, 
Non Sedating OR Non-Sedating H1 Antihistamines OR Second Generation Antihistamines 
OR Antihistamines, Second Generation OR Third Generation H1 Antagonists OR  
Brompheniramine OR Promethazine OR Hydroxyzine OR Tripelennamne OR 
Dexchlorpheniramine OR Cyproheptadine OR Chlorpheniramine OR Diphenhydramine OR 
Dimenhydinate OR Doxylamine OR Dimetinidene OR Cyclazine OR Meclizine OR 
Triprolidine OR Dexchlorpheniramine OR Chloropyramine OR Piperazine Derivatives OR 
Clemastino OR Pheniramire OR Mizolastine OR Triflupromazine OR Chlorphenoxamine 
OR Buclzine OR Prochorperazine OR Dicyclomine OR Phenothiazine OR Pheniramine OR 
Methapyrilene OR Thonzylamine OR Pyrilamine OR Tripelennamine OR Phenyltoloxamine 
OR Buclizine Or Chlorothen OR Cetirizine OR Fexofenadine OR Loratidine OR 
Levocetrizine OR Desloratidine OR Terfenadine OR Astemizole 
2 limit 1 to humans  
3 Malformation OR Abnormality, Congenital OR Congenital Abnormality OR Deformities 
OR Deformity OR Congenital Defects OR Congenital Defect OR Defect, Congenital OR 
Defects, Congenital OR Abnormalities, Congenital OR Birth Defects OR Birth Defect OR 
Defect, Birth OR Defects, Birth OR embryopathy OR Pregnancy Outcomes OR Outcome, 
Pregnancy OR Pregnancy Complication OR Live Birth OR Stillbirth OR Premature Birth 
OR Prematurity OR Spontaneous Abortion OR Induced Abortion OR Therapeutic Abortion 
OR Miscarriage OR  Low Birth Weight 
4 limit 3 to humans 
5 2 AND 4 
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Appendix 6: Data extraction form for Chapter 6. 
Study Title:                             Drug Name:                 First Author:              Year:                      Journal:          
Design:  retrospective  prospective cohort case control randomized      Reference #:         
Study Location (year):             First Trimester:       Quality Score:        Type of Control:        Publication Type:  
 # of pregnancy # of live birth Comments 
Exposed    
Control    
 # of major malformation Total  
Exposed    
Control    
 # of preterm infants Total  
Exposed    
Control    
 # of spontaneous abortions Total  
Exposed    
Control    
 # of stillbirths Total  
Exposed    
Control     
 #  of low birth weight infants Total  
Exposed    
Control    
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Appendix 7: Characteristics of the included studies for Chapter117 6. 
Table 6. Characteristics of the included studies. 
First author 
(publication year) 
Publication 
type (study 
design) 
H1-AHs drug names Type of control Pregnancy 
outcomes 
measured 
Comments 
GPRG (1963) [23] Peer-review 
journal (cohort 
study) 
Collection of H1-AHs Not exposed to any H1-
AHs  
MM, S, St For NVP meta-
analysis, doxylamine 
data was only used 
Mellin (1963) [24] Peer-review 
journal (cohort 
study) 
Meclizine, 
dimenhydrinate, 
cyclizine 
Exposed to H1-AHs 
under study before or 
after pregnancy 
MM Used for NVP meta-
analysis 
Bunde (1963) [25] Peer-review 
journal (cohort 
study) 
Doxylamine Healthy matched control MM Used for NVP meta-
analysis 
Yerushalmy (1965) 
[26] 
Peer-review 
journal (cohort 
study) 
Meclizine, cylizine Not exposed to any H1-
AHs 
MM Used for NVP meta-
analysis 
Erez (1971) [27] Peer-review 
journal (cohort 
study) 
Hydroxyzine NVP group that took 
placebo 
MM, S Used for NVP meta-
analysis 
Milkovich 
(1976) [28] 
Peer-review 
journal (cohort 
study) 
Collection of H1-AHs NVP group that did took 
treatment and NVP free 
group 
MM Used for NVP meta-
analysis 
Kullander (1976) 
[29] 
Peer-review 
journal (cohort 
study) 
Collection of H1-AHs Not exposed to any H1-
AHs 
MM, P Used for NVP meta-
analysis 
Heinonen (1977) 
[30] 
Book (cohort 
study) 
Collection of H1-AHs Not exposed to H1-AHs 
under study 
MM Excluded in the 
sensitivity analysis 
Newman (1977) 
[31] 
Peer-review 
journal (cohort 
study) 
Collection of H1-AHs Not exposed to any H1-
AHs 
MM Used for NVP meta-
analysis 
Shapiro (1978) 
[32] 
Peer-review 
journal (cohort 
study) 
Meclizine Not exposed to H1-AHs 
under study 
MM Excluded in the 
sensitivity analysis 
Smithells (1978) 
[33] 
Peer-review 
journal (cohort 
study) 
Doxylamine Exposed to doxylamine 
in the non-first trimester 
of pregnancy 
MM Used for NVP meta-
analysis 
H1-AHs: H1 Antihistamines, MM: Major Malformation, P: Prematurity, S: Spontaneous, St: Stillbirth, L: Low birth weight 
  
176 
 
Table 6. Characteristics of the included studies (continue). 
First author 
(publication 
year) 
Publication 
type (study 
design) 
H1-AHs drug names Type of control Pregnancy 
outcomes 
measured 
Comments 
Jick (1981) [34] Peer-review 
journal (cohort 
study) 
Doxylamine Not exposed to any 
H1-AHs 
MM Used for NVP meta-analysis 
Fleming (1981) 
[35] 
Peer-review 
journal (cohort 
study) 
Doxylamine Not exposed to any 
H1-AHs 
MM Used for NVP meta-analysis 
Gibson (1981) 
[36] 
Peer-review 
journal (cohort 
study) 
Doxylamine, dicyclome Not exposed to any 
H1-AHs 
MM Used for NVP meta-analysis 
Michaelis 1 
(1983) [37] 
Peer-review 
journal (cohort 
study) 
Doxylamine Healthy matched 
control 
MM Used for NVP meta-analysis 
Michaelis 2 
(1983) [37] 
Peer-review 
journal (cohort 
study) 
Meclizine Healthy matched 
control 
MM Used for NVP meta-analysis 
Seto (1993) [38] Peer-review 
journal (cohort 
study) 
Brompheniramine Healthy matched 
control 
MM - 
Pastuzak (1996) 
[39] 
Peer-review 
journal (cohort 
study) 
Astemizole Healthy matched 
control 
MM, S, St - 
Einarson (1997) 
[40] 
Peer-review 
journal (cohort 
study) 
Cetirizine, hydroxyzine Healthy matched 
control 
MM, S, St - 
Schatz (Michigan 
Medical study) 
(1997) [41] 
Guest editorial 
(cohort study) 
Collection of H1-AHs Not exposed to H1-
AHs under study 
MM Excluded in the sensitivity 
analysis 
Wilton (1998) 
[42] 
Peer-review 
journal (cohort 
study) 
Cetirizine, loratidine Not exposed to any 
H1-AHs 
MM, P, S - 
Loebstein (1999) 
[43] 
Peer-review 
journal (cohort 
study) 
Terfenadine Healthy matched 
control 
MM, P, St, L - 
Kallen (2002) 
[44] 
Peer-review 
journal (cohort 
study) 
Collection of H1-AHs that 
is used for allergy and 
Collection of H1-AHs that 
is used for NVP 
General population 
that is not exposed to 
any H1-AHs  
MM, P For the all H1-AHs meta-
analysis, data for allergy was 
used and for NVP meta-analysis, 
data for NVP was used 
H1-AHs: H1 Antihistamines, MM: Major Malformation, P: Prematurity, S: Spontaneous, St: Stillbirth, L: Low birth weight 
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Table 6. Characteristics of the included studies (continue).  
First author 
(publication year) 
Publication type 
(study design) 
H1-AHs drug 
names 
Type of control Pregnancy 
outcomes 
measured 
Comments 
Kallen & Mottet 
(2003) [45] 
Peer-review journal 
(cohort study) 
Meclizine General population that is 
not exposed to Meclizine 
MM Excluded in the 
sensitivity analysis 
Bsat (2003) [46] Peer-review journal 
(cohort study) 
Promethazine NVP group that took non 
H1-AHs treatment 
MM Used for NVP meta-
analysis 
Diav-Citrin (2003) 
[47] 
Peer-review journal 
(cohort study) 
Collection of H1-
AHs 
Healthy control MM, P, S - 
Moretti (2003) 
[48] 
Peer-review journal 
(cohort study) 
Loratidine Healthy matched control MM, S, St - 
Paulus (2004) [49] Abstract (cohort 
study) 
Cetirizine, 
levocetirizine 
Healthy control MM, S - 
Boskovic (2004) 
[50] 
Peer-review journal 
(cohort study) 
Doxylamine Healthy matched control 
(with no NVP) 
MM, S, St, L Used for NVP meta-
analysis 
Weber (2008) [51] Peer-review journal 
(cohort study) 
Cetirizine Healthy control MM, P, S - 
Ashkenazi (2013) 
[52] 
Peer-review journal 
(cohort study) 
Doxylamine NVP group that took non 
H1-AHs treatment 
MM, P, S, L Used for NVP meta-
analysis 
Etwel (2014) [16] Peer-review journal 
(cohort study) 
Cetirizine Healthy matched control MM, P, S, St  
 
For P we used that data 
without confounders 
Aldridge (2014) 
[7] 
Peer-review journal 
(cohort study) 
Collection of H1-
AHs 
Healthy matched control P, S, St H2-AHs data was 
excluded 
Eskenazi (1982) 
[53] 
Peer-review journal 
(case control study) 
Doxylamine Not exposed to 
Doxylamine 
MM Minor malformation 
was excluded 
Czeizel (2005) 
[54] 
Peer-review journal 
(case control study) 
Dimenhydrinate Not exposed to 
Dimenhydrinate 
MM - 
Gilboa (2009) [55] Peer-review journal 
(case control study) 
Collection of H1-
AHs 
Not exposed to any H1-
AHs 
MM - 
Li (2013) [3] Peer-review journal 
(case control study) 
Collection of H1-
AHs 
Not exposed to any H1-
AHs 
MM - 
H1-AHs: H1 Antihistamines, MM: Major Malformation, P: Prematurity, S: Spontaneous, St: Stillbirth, L: Low birth weigh 
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